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Abstract 
The HIV-1 surface protein, Envelope (Env), is covered in asparagine-linked glycans, which interact 
with the human immune system and are thus important as potential vaccine targets. Laboratory studies 
have shown that the glycan type and form can differ substantially at each glycan site on Env clones. 
However, these studies are limited by time and cost and rely on biosynthetic assumptions to elucidate 
the structure of branched glycans. Furthermore, glycan heterogeneity creates challenges when 
determining the three-dimensional structure of Env, which has resulted in the use of methods that 
restrict glycan processing to produce uniform glycans for these studies. Computational methods are 
used to complement the laboratory studies; however, due to the limitations of modelling software, even 
computational studies have focussed on uniformly glycosylated Env models using a limited set of 
high-mannose glycans, rather than a mix of glycan types.  
To bridge this gap, this study set out to examine the structural differences of two computationally 
glycosylated HIV-1 Env trimers, one uniformly glycosylated, and the other based on the heterogeneous 
glycosylation of a laboratory determined gp160 strain. A secondary aim was to estimate whether the 
type of glycan is predictable using computational techniques, since these are less expensive and time-
consuming than laboratory studies.  
Using 500 ns molecular dynamics (MD) simulations, it was found that the heterogeneously 
glycosylated trimer had 64% greater stability, likely due to the presence of 25% more hydrogen bonds, 
as well as stabilising bonds which appeared to prevent asymmetrical movements. Furthermore, by 
focussing on the heterogeneously glycosylated trimer, a computational method based on surface area 
was explored to estimate the accessibility to enzymes involved in glycan processing, and to use this 
measure as a predictor of the glycan type.  
The results of this study highlight the differences between a uniformly, and a heterogeneously, 
glycosylated trimer, and suggest that previous MD studies, which used uniformly glycosylated trimers, 
may not sufficiently describe the structural dynamics of HIV-1 Env. Notably, complex glycans appear 
to stabilise the trimer to a greater extent than the high-mannose glycans used in previous studies. Thus, 
it is evident that research on Env models should incorporate a more diverse set of glycans in order to 
deepen our understanding of the dynamics of Env, which will, in turn, further our understanding of its 
interactions with antibodies and anti-HIV compounds.  
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1. Introduction 
If I have seen further, it is only by standing on the shoulders of giants ~ Isaac Newton 
 
1.1. Brief History and Discovery of the Human Immunodeficiency Virus 
In 1983, the causal agent of Acquired Immunodeficiency Syndrome (AIDS) was identified as the 
Human Immunodeficiency Virus (HIV) by two independent laboratories (Barré-Sinoussi et al., 1983; 
Gallo et al., 1983). The virus was found to primarily target CD4+ T cells, depleting them over time to 
cause the immune deficiencies that had been observed (Klatzmann et al., 1984). Due to its high genetic 
variability, a cure has proven elusive, and HIV has gone on to become a global pandemic that has 
caused more than 35 million deaths (WHO, 2016).  
HIV has two types – HIV-1, and HIV-2 – and it is the more virulent HIV-1 which is responsible for 
the current global pandemic. There are 4 HIV-1 groups comprising lineages M (main), N (non-M or 
O), O (outlier) and, most recently identified, group P (Buonaguro, Tornesello and Buonaguro, 2007; 
Plantier et al., 2009). Each of these arose from independent cross-species transmission events from 
chimpanzees or gorillas to humans (Sharp and Hahn, 2011). The main group, M, is responsible for the 
majority of HIV-1 cases worldwide, which numbered approximately 36.9 million at the end of 2017 
(WHO, 2017). It is made up of 9 clades/subtypes: A, B, C, D, E, F, G, H, J and K, as well as 
recombinant forms that result in a mix of clades.  Clades A, B, and C are the most common forms of 
HIV-1: Clade A is found mostly in East Africa, Central Asia, and Eastern Europe; Clade B in America, 
Western Europe and Australia; and Clade C in Southern Africa, the Horn of Africa, and India 
(McCutchan, 2006). Clade C alone accounts for more than 50% of HIV-1 cases (Günthard and 
Scherrer, 2016; Shrivastava et al., 2018).  
Given that the majority of HIV-1 cases occur in the developing world, problems of access to HIV-1 
interventions such as anti-retrovirals (ARVs) and highly active anti-retroviral therapy (HAART) 
persist (Atun et al., 2016; Stephenson and Barouch, 2016). While these interventions have changed 
the outlook of HIV-1 from being a lethal disease to a manageable condition, only 2 in 5 people have 
access to ARVs (Stephenson and Barouch, 2016), highlighting the need for a vaccine to help bring the 
HIV-1 pandemic under control. Most vaccines are created using neutralising antibodies (NAbs) to 
guide vaccine design (Kwong, Mascola and Nabel, 2011), and thus an important step towards a vaccine 
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for HIV-1 has been understanding the immune responses of the body once HIV-1 infection has 
occurred.  
1.2. The Course of an HIV-1 Infection 
The majority of HIV-1 infections are caused by a single founder virus, passed across the mucosal 
membrane of an HIV-positive person to an HIV-negative person (Keele et al., 2008). There is a period 
of about 10 days where viral DNA cannot be detected in the plasma, known as the eclipse phase 
(McMichael et al., 2010). Thereafter, viral levels increase exponentially, mediated by dendritic cell 
dissemination of HIV-1 to the lymphoid tissue (Geijtenbeek et al., 2000). The gut-associated lymphoid 
tissue (GALT) is particularly affected, and a vast number of CD4+ T cells are lost from this immune 
cell rich region during acute infection (Figure 1) (Brenchley et al., 2004).  
As the viral load increases, naïve B cells are exposed to HIV-1, and the first antigen-specific B-cells 
appear, although their expressed antibodies are not yet capable of neutralising the virus. Within 12 
weeks of infection, the body starts to produce NAbs against HIV-1 (Figure 1) (Richman et al., 2003). 
Thereafter, 3 – 6 months post-infection, the viral load attains a stable level, known as the viral set point 
(McMichael et al., 2010), and CD4+ T cell levels rise again with the decrease in the viral load. This 
chronic phase can last for years, especially with treatment. Without treatment, an HIV-1 infection will 
usually progress, leading to immune suppression, AIDS-related illnesses, and finally death as CD4+ T 
cells are destroyed.  
In 10 – 30% of HIV-positive individuals, broadly neutralising antibodies (bNAbs) are produced after 
2 to 3 years of infection (Figure 1) (Sather et al., 2009; Walker et al., 2010; Gray et al., 2011). Unlike 
the NAbs produced by the 12th week of infection, these antibodies are capable of neutralising more 
than one strain of the virus. Given that the founder virus rapidly evolves to form a swarm of millions 
of variant viruses known as a “quasi-species” (Figure 1) (Eigen and Schuster, 1977; Domingo et al., 
1978), this broad neutralising ability is of great interest to vaccine research. By exploiting the co-
evolution of the virus and the antibody response (Liao et al., 2013), researchers hope to use rational 
HIV-1 immunogen design in order to trigger the formation of bNAbs.  
There have been numerous vaccine trials (Klein et al., 2013), but the most effective HIV-1 vaccine 
had only a moderate efficacy of 31.2% (Rerks-Ngarm et al., 2009). It is clear that better immunisation 
strategies are needed, and a fuller understanding of the structure of HIV-1 and its relation to bNAbs 
has emerged as a vital step towards this goal.  
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Figure 1: Changes in disease markers and immune response over the course of an HIV-1 infection 
Measures of disease progression, along with stages in HIV evolution and antibody maturation over the course of an HIV-
1 infection. Adapted from Grossman et al. 2006.  
HIV Evolution: A single founder virus begins the HIV-1 infection, and evolves to form a quasi-species made up of millions 
of variants. Antibody maturation: Naïve B cells are exposed to HIV-1, resulting initially in the production antibody specific 
B cells. Within 12 weeks NAbs are produced. In 10 – 30% of individuals, bNAbs are produced within 2-3 years of infection. 
Eclipse phase: short ~10 day period after infection when the virus cannot be detected. Acute phase: a period of weeks 
where viral load increases rapidly, decimating the CD4+ T cell population until it is controlled by an increase in immune 
activation, and settles at the viral set point. Chronic phase: a period of years of interplay between immune activation and 
HIV-1 immune evasion, with a steady decrease in CD4+ T cell count. AIDS: Once the CD4+ T cell count reaches a critical 
level (<200), the levels of viraemia can no longer be controlled. The increased viral load depletes the remaining CD4+ T 
cells, and opportunistic infections set in, leading to death. 
* All images are my own unless otherwise stated  
 
1.3. The Structure and Lifecycle of HIV-1 
HIV-1 is an enveloped retrovirus of the Lentivirus genus. It has an average diameter of 145nm and is 
made up of 9 genes  (Figure 2A) (Briggs et al., 2003). Encased inside the host-derived lipid membrane, 
within the viral matrix, is the conically shaped capsid protein (Figure 2A). This contains viral enzymes, 
accessory proteins, and two copies of single stranded genomic RNA tightly bound to zinc-finger 
nucleocapsid proteins (Summers et al., 1992; Frankel and Young, 1998). On the surface of the virion 
are 5 – 15 envelope proteins (Env), which extend outside the lipid membrane (Figure 2A and B) 
(Brandenberg et al., 2015), and are covered in a huge variety of N-linked glycans.  
Glycans are grouped into three broad classes: high mannose, where only mannose (Man) residues 
extend the Man3GlcNAc2 core (Figure 2C); hybrid glycans, where one arm is extended by mannose 
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residues, and the other by the addition of N-acetylglucosamine (GlcNAc) residues; and complex 
glycans, which are extended by arms, or “antennae”, each connected by a GlcNAc residue to the core. 
Complex glycans are commonly described along with their number of antennae (e.g. the biantennary 
complex glycans in Figure 2C), and can have up to six branches (Stanley, Taniguchi and Aebi, 2017). 
The Env trimer spikes are crucial for HIV-1 infectivity, since they interact with human CD4+ T cells 
during the processes of binding to the CD4 receptor and a CC or CXC chemokine coreceptor, fusing 
the host and viral membranes, and facilitating entry of the viral capsid into the newly infected immune 
cell (Engelman and Cherepanov, 2012). Because these interactions require conformational changes in 
Env, it is a metastable complex (Julien, Cupo, et al., 2013). The prefusion state of Env is present on 
circulating virions; upon receptor binding, Env is activated, and undergoes conformational changes 
that result in membrane fusion and the entry of the viral core into the host cell (Chan and Kim, 1998). 
Once HIV has entered the cell, viral reverse transcriptase (RT) creates a double-stranded copy of viral 
DNA from the two ~9 kilobase RNA strands in a low fidelity copying process, with an average error 
rate of 1 error for every 1700 nucleotides (Roberts, Bebenek and Kunkel, 1988). This high error rate, 
along with the presence of 2 RNA strands, which allows for recombination to occur, contributes to the 
Figure 2: Structure of HIV-1 and extensive heterogeneity of its glycan shield 
A: Stylised drawing of HIV-1. B: Magnification to illustrate the location of glycans on the HIV-1 Envelope trimer. C: A 
small subset of the vast glycan diversity in the glycan shield, shown in Consortium for Functional Genomics (CFG) 
Notation. The broad categories of glycan are indicated (high mannose, hybrid and complex), and the Man9GlcNAc2 and 
Man5GlcNAc2 glycans are shown, along with the Man3GlcNAc2 glycan which forms the core of all N-linked glycans. 
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genetic diversity of HIV-1 (Freed, 2015). The newly formed DNA is transported across the nuclear 
membrane to enter the host nucleus. Here, it is integrated into the host genome by viral integrase in 
order to carry out replication (Engelman and Cherepanov, 2012).  
At this point, if the CD4+ T cell enters a resting memory state, rather than replicating, the virus will 
stay embedded in the genome as a latent viral reservoir (Siliciano and Greene, 2011). Otherwise, viral 
replication takes place, using the host machinery to transcribe a copy of viral RNA with the help of 
the viral Tat protein (Engelman and Cherepanov, 2012). The HIV-1 RNAs are transported to the 
cytoplasm, where they use the host machinery to produce viral proteins (Freed, 2015). 
The HIV-1 genome is translated into 3 major polyproteins: Gag, Gag-Pol, and Env. These are then 
broken down to form individual proteins. The 55 kDa Gag polyprotein forms the major internal 
structural proteins:  the matrix, capsid and nucleocapsid, as well as the budding protein, p6 (Freed, 
2015). The 160 kDa Gag-Pol polyprotein precursor contains the viral enzymes: reverse transcriptase, 
protease and integrase (Freed, 2015). The Env polyprotein is modified during the process of protein 
translation with sugars, known as glycans, being added in the process of glycosylation (Figure 2B and 
C) (Checkley, Luttge and Freed, 2011). The glycans make up roughly half of the molecular weight of 
Env (Lasky et al., 1986). The 160 kDa gp160 Env polyprotein is cleaved by furin to form the gp120 
and gp41 subunits (Checkley, Luttge and Freed, 2011). These subunits remain non-covalently 
associated as a protomer; three covalently-bound protomers make an HIV-1 Env trimer spike (Figure 
2B) (Checkley, Luttge and Freed, 2011).  
The Gag and Gag-Pol polyproteins, along with two copies of genomic RNA per virion, assemble at 
the cell membrane, where Gag recruits lipid rafts made up of cholesterol- and glycophingolipid-
enhanced microdomains. The lipid rafts are believed to be important for viral assembly. Glycosylated 
Env trimers also assemble at the host cell membrane, with their gp41 cytoplasmic tails embedded 
within the membrane, and the gp120 components extending outside the membrane. The model of 
incorporation of Env into new immature viruses is not entirely clear, but evidence points to the 
interaction of the gp41 cytoplasmic tail of Env and the matrix constituent of Gag during the 
incorporation process (Freed, 2015).  
The p6 domain of the Gag polyprotein hijacks the cellular endosomal sorting complex required for 
transport (ESCRT) in order to mediate the budding off of a new virion by pinching the host cell 
membrane together. During or soon after viral release, the viral protease cleaves sites in the Gag and 
Gag-Pol polyproteins, triggering viral maturation (Freed, 2015). The new viruses then go on to infect 
other immune cells.  
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Having budded off from the host membrane, the Gag and Gag-Pol viral proteins are contained within 
the host-derived viral membrane, and the surface protein, Env is the only exposed HIV-1 antigen that 
can be targeted by neutralising antibodies (Wyatt and Sodroski, 1998; Zhou et al., 2007). Env thus 
forms the basis of much research, as it represents an important vaccine target.  
1.4. The HIV-1 Envelope 
The trimeric Env protein is made up of 3 covalently associated gp120-gp41 protomers (Liu et al., 
2008). The gp120 subunit has five variable regions (V1-5) separated by disulphide bonds into flexible 
loops. These are interspersed with constant regions (C1-5) (Figure 3 A – C) (Starcich et al., 1986; 
Figure 3: Structure of the HIV-1 Envelope 
A and B: (A) Side view and (B) Top view of HIV-1 Env protein showing gp41 ectodomain, and variable and constant regions 
of gp120. Colours of each region correspond to those in C. C: Linear schematic of HIV-1 Env regions and the PNGSs within 
each. Not to scale. D and E: (D) Side view and (E) Top view of glycosylated HIV-1 Env protein. Glycans are numbered 
according to the HXB2 reference sequence (See Supplementary Figure 1). Colours here were used to create the maximum 
distinction between neighbouring glycans, and do not relate to the regions presented in C.  
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Willey et al., 1986; Leonard et al., 1990). The constant regions are important for binding to the CD4 
receptor when infecting CD4+ T cells. This binding occurs in a recessed pocket within gp120, starting 
off by early contact with the CD4-binding loop (Figure 3A and B) (Zhou et al., 2010; Wu et al., 2011). 
The variable regions on the other hand play an important role in immune evasion, as their length and 
sequence change over the course of an infection, creating a challenge for circulating antibodies (Curlin 
et al., 2010). The V1/V2 and V3 loops make up the trimer apex, while the V4 and V5 loops project 
outwards from the gp120 core (Figure 3A and B) (Ward and Wilson, 2015). The gp41 subunit is made 
up of three major domains: an extracellular ectodomain, a transmembrane domain, and a cytoplasmic 
tail (Checkley, Luttge and Freed, 2011).  
Each gp120-gp41 protomer has 25 to 30 highly polar N-linked glycans, totalling ~90 glycans if all 
potential sites are glycosylated (Figure 3C – E) 1 (Kong, Stanfield and Wilson, 2013; Cao et al., 2017). 
Importantly, glycans are the first point of contact with the human immune system – affecting which 
cells HIV-1 will enter according to the CC or CXC chemokine co-receptors (Wood et al., 2013), 
shielding protein epitopes from antibodies (Wei et al., 2003), and paradoxically also forming targets 
for broadly neutralising antibodies (Walker et al., 2010; Gray et al., 2011). This makes them important 
as vaccine and therapeutic targets.  
The increased glycosylation of viral sequences over the course of an infection highlights the 
importance of glycans to immune evasion (Sagar et al., 2006; Curlin et al., 2010). This trait has been 
successfully exploited by creating a “glycan hole” through the removal of 4 glycans in order to prime 
powerful neutralising antibodies (Zhou et al., 2017). A natural hole seen on the BG505 SOSIP.664 
construct was also found to elicit potently neutralising monoclonal antibodies (McCoy et al., 2016). 
Interestingly, removal of a single glycan does not always result in a hole, but instead can result in 
structural rearrangements of the glycan shield (Ferreira et al., 2018). Similarly, glycans have been used 
to mask unimportant antibody targets on the Env trimer in order to redirect the immune response 
towards important epitopes (Duan et al., 2018). These approaches may be helpful in the eventual 
design of a vaccine.  
The process whereby glycans are attached to the protein as it is made is known as glycosylation. 
Glycosylation of HIV-1 Env is carried out by host enzymes found in the endoplasmic reticulum (ER), 
and Golgi apparatus (Doores, 2015). In the ER, the precursor sugar, Glc3Man9GlcNAc2, is added to 
the Env polyprotein at asparagine residues found within special motifs, known as potential N-linked 
                                                 
1 Glycans are referred to using the HXB2 numbering system (See Supplementary Figure 1 for sequence alignment). This 
convention is used throughout this work.  
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glycosylation sites (PNGSs). PNGSs have the amino acid sequence Asparagine-X-Threonine/Serine 
(or NXT/S), where X can be any amino acid except proline. (Kornfeld and Kornfeld, 1985). Once 
attached to Env at PNGSs, the precursor sugars are processed to form Man9GlcNAc2 (henceforth 
abbreviated to Man9) (Moremen, Tiemeyer and Nairn, 2012).  
The barrel-shaped ER α-mannosidase I enzyme (ER Man I) removes one mannose residue from Man9, 
to form the Man8GlcNAc2 glycan. After this, the glycosylated gp160 Env polyproteins group together 
(usually in sets of three) in the process of oligomerisation, and move to the Golgi apparatus. (Earl, 
Doms and Moss, 1990; Moremen, Tiemeyer and Nairn, 2012; Xiang, Karaveg and Moremen, 2016).  
In the Golgi, the glycans are trimmed to form Man5GlcNAc2 (abbreviated to Man5) by Golgi α-
mannosidases IA – C (Doores et al., 2010). The α-mannosidase III enzyme removes the two outermost 
mannose residues to form Man3GlcNAc2, which is the core structure of all N-linked glycans (Stanley, 
Taniguchi and Aebi, 2017). Sugar residues are added one by one, elongating the glycans, which 
progress through a hybrid stage to form complex glycans (Figure 4).  
 
The availability of hexosamine is an important factor in determining the level of branching of hybrid 
and complex glycans (Lau et al., 2007).  Glycans with two branches are referred to as bi-antennary 
(such as the Complex-glycan in Figure 4), those with three are referred to as tri-antennary, and those 
with four branches are referred to as tetra-antennary.  
Figure 4: Simplified overview of glycans used and their degree of processing 
Man9 is the first glycan in the glycosylation assembly line. It is trimmed, residue by residue, to form Man5. As other sugar 
residues are added, the glycan progresses through a hybrid stage before complex glycans are formed. Glycans are depicted 
in order from less to more processed with CFG notation (left) and structural visualisation (right) shown for each glycan. 
Blue boxes are used to highlight the Man3GlcNAc2 core of each glycan. The set of glycans shown is important to this 
work.  
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Where processing enzymes cannot fit due to spatial constraints, glycans remain underprocessed, 
resulting in the characteristic high mannose areas found on HIV-1 – the intrinsic mannose patch (IMP) 
on the outside of the gp120 monomers (Doores et al., 2010), as well as the trimer-associated mannose 
patch (TAMP) in the centre of the trimer (Pritchard, Vasiljevic, et al., 2015). These mannose patches 
are conserved across strains and over the course of an HIV-1 infection (Coss et al., 2016). The 
relationship between solvent accessible surface area and glycan processing has recently been 
investigated on a large set of glycoproteins from the Protein Data Bank, highlighting the link between 
spatial constraints and lower levels of glycan processing (Suga, Nagae and Yamaguchi, 2018).  
The characteristic high mannose regions have been shown to be important to the elicitation of bNAb 
responses (Lavine et al., 2012), and studies using kifunensine to restrict glycan processing beyond 
Man9 have been found to improve the neutralising ability of V3 Abs for JR-FL Env immunogens, and 
V2 and V3 Abs for BaL viral Env immunogens (Upadhyay et al., 2014).   
Importantly, although the glycosylation process takes place in an ordered assembly line, factors such 
as spatial constraints, substrate availability, speed of translocation, cell type, rotation about glyosidic 
linkages, viral strain, amino acid divergence, and enzyme compartmentalisation result in extensive 
glycan heterogeneity (Figure 2C) (Varki et al., 2009; Pritchard, Harvey, et al., 2015). Thus, after 
processing, a Man9 glycan may result in any of multiple Man5-8GlcNAc forms (depending on which 
residues are removed in turn); it may be reduced to the Man3GlcNAc2 core and not further extended; 
it could result in a bi-antennary hybrid glycan, or a hexa-antennary complex glycan, or any of 
multifarious glycan forms – not all of which are yet known. This heterogeneity manifests within and 
across sites on any single Env, as well as between the different Envs on the same viral surface, within 
the viral isolate and between different strains (Doores, 2015; Behrens et al., 2016; Panico et al., 2016; 
Cao et al., 2017, 2018).  
1.5. Structural Studies of the HIV-1 Envelope 
1.5.1 Crystallisation 
Glycan heterogeneity has created special challenges for structural studies of Env. Crystallisation is 
made difficult by the presence of different glycoforms and glycan conformations, since these disrupt 
the uniformity that is required for the formation of crystals (Chang et al., 2007). For decades, X-ray 
crystallography was limited to proteins with low levels of glycosylation; this was commonly accepted 
as not exceeding 1 PNGS per 100 amino acids (Gristick, Wang and Bjorkman, 2017). HIV-1 Env by 
contrast has roughly 1 PNGS for every 20 amino acids, and was thus initially studied through removing 
PNGSs, using high mannose glycosylation systems, deglycosylating the proteins, or a combination of 
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these approaches (Gristick, Wang and Bjorkman, 2017). Indeed, the first crystal structures of gp120 
were achieved using insect cell expression systems to result in fewer glycans of a high or pauci-
mannose type, and then using endoglycosidases EndoH and EndoD to remove glycans prior to 
crystallisation (Kwong et al., 1998; Wyatt et al., 1998; Kwong, 1999). 
As the importance of glycans has become more apparent by their presence in bNAb epitopes, it has 
become common to attempt to preserve more of the glycan shield in experimental studies. For crystal 
studies, homogeneity is still desirable, and thus glycan processing has been constrained in order to 
produce ordered crystals. Kifunensine is used to prevent further processing from the Man9 starting 
glycan; GnTI-deficient cells are used to stop processing from Man5; and swainsonine is used to create 
a shield of hybrid-type glycans (Chang et al., 2007).  
Along with these methods of inhibiting glycan processing to maintain uniformity, antibodies have also 
been used to shield the glycans they are complexed with, along with surrounding glycans (Julien, 
Cupo, et al., 2013). This allows insight into the specific glycoforms that are present in the bound and 
shielded area. The discovery of numerous and diverse bNAbs since 2009 (Montefiori, 2009; Scheid et 
al., 2009; Simek et al., 2009; Walker et al., 2009) has drastically improved crystal screening, allowing 
increasingly complete crystal structures to be resolved. This played an important part in obtaining 
HIV-1 Env trimer crystal structures.  
Achieving native trimeric crystal structures took many years; hindered by the low yield of viral spikes 
and the metastable nature of the Env glycoprotein, researchers turned to recombinant forms. This 
started in the early 2000s, with the initial forms of the JR-FL SOSIP trimer construct (Binley et al., 
2000; Sanders et al., 2002), but it was not until 2013 that the critical breakthrough came in the form 
of the clade A BG505-SOSIP.664 recombinant trimer (Sanders et al., 2013).  By adding disulphide 
bonds between the gp120 and gp41 subunits (SOS) to stop their dissociation, substituting an isoleucine 
in gp41 with a proline (IP) to prevent fusion-induced changes, and truncating the glycoprotein at 
position 664 to include only the region of Env outside the plasma membrane, the Moore lab was able 
to crystallise the trimer in its prefusion state (Sanders et al., 2013). This recombinant represents one 
of the leading immunogen prospects for an HIV-1 vaccine (Doores, 2015; Sanders et al., 2016).  
In 2016, fully glycosylated trimers, that is, where the free glycans were not removed by 
endoglycosidases prior to crystallisation, were crystallised by the Kwong lab. Using GnTI-deficient 
cell lines, which resulted in high mannose trimers of glycoforms Man5-9GlcNAc2, along with antibodies 
PGT122, 35O22, and VRC01, they crystallised trimers from clades A (BG505.664), B, and G, 
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managing to preserve ~50% of the glycan mass (Stewart-Jones et al., 2016). This represented a great 
advance in visualising the glycan shield of HIV-1 Env. 
1.5.2. Electron Microscopy 
While crystallisation is viewed as the “gold standard” of structural biology, it is important not to 
overlook the enormous contribution of electron microscopy (EM) when it comes to elucidating 
glycoprotein structure. In contrast to crystallisation, EM is enhanced by glycans, as they provide more 
mass and features, allowing computer algorithms greater fidelity in the identification, sorting, and 
aligning processes (Crispin, Ward and Wilson, 2018). Notably EM played a vital role in developing 
the BG505 SOSIP.664 immunogen (Sanders et al., 2013).  
1.5.3. Mass Spectrometry and Liquid Chromatography Studies 
Crystallisation and electron microscopy have been very useful in revealing the HIV-1 Env protein 
structure and glycan positions; however these methods represent a form of averaging when it comes 
to the chemical composition of the glycans themselves (Crispin, Ward and Wilson, 2018). Given the 
importance of glycans to bNAb epitopes, there has been an increasing interest in more precisely 
determining the chemical makeup, and variability in this makeup (or microheterogeneity) of glycans 
at each PNGS on HIV-1 Env using mass spectrometry (MS) and liquid chromatography (LC).  
The first study was carried out nearly 30 years ago on recombinant monomeric gp120 using reverse-
phase high-performance liquid chromatography (RP-HPLC) and pointed to a high mannose dominated 
glycan shield (Leonard et al., 1990); since then mass spectrometry advances have allowed more 
detailed insight into the microheterogeneity and occupancy levels of glycans at each PNGS. Studies 
were initially restricted to recombinant monomeric gp120 constructs due to the challenges of isolating 
native virions. Soon the comparison of recombinant gp120 with virus associated gp120 facilitated the 
characterisation of the intrinsic mannose patch, which persists across strains and is distinct from host-
cell processing (Doores et al., 2010). The eventual move to using recombinant trimers in mass 
spectrometry hinted at a difference in processing from a gp120 monomer (Guttman et al., 2014); this 
was fully clarified in a in a hydrophilic interaction ultra-performance liquid chromatography (HILIC-
UPLC) study with the identification of the trimer-associated mannose patch (Pritchard, Vasiljevic, et 
al., 2015) 
Recent mass spectrometry studies  (Behrens et al., 2016; Panico et al., 2016; Cao et al., 2017, 2018) 
focus on the glycan specificity at each glycosylation site on trimeric Env. Two main approaches have 
been favoured: firstly, analysing released glycans by mass spectrometry; and secondly, analysing 
whole glycopeptides by mass spectrometry.  
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Behrens et al. (2016) used a quantitative approach to glycopeptide analysis. They first used a HILIC-
UPLC-MS approach with fluorescently labelled glycans to create a database of the glycans present on 
the BG505 SOSIP.664 trimer. This was then used as a benchmark for a subsequent mass spectrometry 
analysis in order to quantify the levels of glycoforms at each site. Panico et al., (2016) used both a 
glycan release and a nonquantitative glycopeptide MS approach on a virion-derived gp120 monomer, 
listing the glycoforms present at each site. Importantly, while mass spectrometry can provide 
information on the quantities of each type of glycan residue present (mannose, galactose, N-
acetylglucosamine, sialic acid or fucose), it loses predictive power as the degree of glycan branching 
increases, since the specific branches and rotational isomers (or rotamers) allocated are based on 
assumptions about glycan processing. (Leymarie and Zaia, 2012).  
Cao et al. (2017 & 2018) used a glycan release approach, which rather than identifying each individual 
glycoform, instead identified the broad classes of glycans present at each site. Using PNGase F and 
EndoH, they could differentiate between complex and high mannose or hybrid glycan types, as well 
as distinguishing between glycosylated and non-glycosylated PNGSs. This allowed sensitive detection 
and complete coverage. Cao et al. (2017) focused on recombinant SOSIP forms from various clades, 
while Cao et al. (2018) compared SOSIP, membrane-bound, pseudovirus-derived and virion-derived 
Env trimers from different strains. Cao et al. (2018) found that viral-derived Env results in glycan 
shields that are composed of a larger percentage of complex glycans than is seen on the SOSIP trimers; 
this may be a challenge to be overcome in immunogen design. 
In spite of the different approaches and Env sources, these studies were largely in agreement, and 
remained consistent with previous research that had identified high mannose areas of gp120, such as 
the intrinsic mannose patch around glycan 332; and complex glycans on gp41, such as at sites 611 and 
618 (Doores et al., 2010; Pritchard, Vasiljevic, et al., 2015). These studies also highlight the 
heterogeneity present on the HIV-1 Env glycan shield. However, in spite of the amazing progress that 
has been made by these studies, the immense variation of the HIV-1 Env means that only a small 
sample of the population of millions of varieties of Env has been sampled by these studies.  
1.5.4. Molecular Dynamics 
Since glycans are difficult to study experimentally due to their heterogeneity (See Section 1.4), they 
are commonly studied through computational means in order to complement experimental results. 
Molecular dynamics (MD) is a computational method that uses Newton’s laws of motion to apply 
force fields to theoretical models in order to create representative simulations of a molecule’s 
movement on a nanosecond timescale (Durrant and McCammon, 2011).  
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MD has been successfully used in HIV-1 Env studies to broaden our understanding of the dynamics 
of the HIV-1 Env glycoprotein. Stewart-Jones et al. (2016) carried out MD studies in conjunction with 
attempting to crystallise fully-glycosylated Env structures. This was useful in beginning to understand 
the dynamic interactions of glycans, and highlighting that most known bNAbs need to accommodate 
glycans within their epitopes. Additionally, the importance of hydrogen bonding to the glycan shield 
was highlighted. Lemmin et al. (2017) carried out a 2 microsecond-long MD simulation on HIV-1 
Env. The unprecedented length of the simulation used in this study enabled the characterisation of 
different structural clusters, which highlighted the asymmetric nature of the HIV-1 Env trimer, as well 
as its potential for dynamic scissoring and opening movements, which influence access to the CD4 
binding site. The phenomenon of scissoring was characterised by the movement of protomers within 
the same plane, like scissor blades moving together and apart, while the opening phenomenon 
consisted of each protomer moving outwards from the centre of the trimer. This finding of scissoring 
differs from what was observed in the 500 ns simulations carried out by Ferreira et al. (2018) – though 
whether this is due to the different structures used, or the shorter length of this study is unclear.  
Previous MD studies of HIV-1 Env have typically used uniformly high mannose glycosylated trimers 
– generally Man5 or Man9, although Man7GlcNAc2 glycans have also been used (Wood et al., 2013; 
Gorman et al., 2016; Stewart-Jones et al., 2016; Yokoyama et al., 2016; Lemmin et al., 2017; Li et 
al., 2017; Moyo et al., 2017; Zhou et al., 2017; Ferreira et al., 2018). While this lines up with the 
results available from crystallisation studies using kifunensine and GnTI-deficient cell lines, it is not 
fully representative of the heterogeneity of the HIV-1 glycan shield. Now with more mass spectrometry 
results available, we can begin to carry out molecular dynamics studies using a mixed set of glycans 
that better represent the glycan shield. 
This project aimed to add to the body of work on the HIV-1 glycan shield, by running molecular 
dynamics on an HIV-1 Env trimer glycosylated with a mix of glycans representative of the processing 
levels seen in mass spectrometry. Using recent mass spectrometry papers to inform glycan specificities 
at each PNGS (Behrens et al., 2016; Panico et al., 2016; Cao et al., 2017), a mixed-glycan model was 
created for molecular dynamics, which was compared to a model uniformly glycosylated with Man9. 
Simulations of 500 ns were generated for both systems, and comparative analysis was carried out.  
The primary aim of this project was to investigate how different types of glycans influence interactions 
with the protein and surrounding glycans. This involved the comparison of the dynamics of a Man9 
glycosylated trimer with those of a heterogeneous mixed-glycan glycosylated trimer. 
The secondary aim of this project was to estimate the potential for glycans to be further processed from 
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the Man9 starting glycan. This was done by carrying out enzyme and solvent accessibility analysis, 
and comparing accessible sites with those which are known to be processed in published works. 
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2. Materials and Methods 
Failure is simply the opportunity to begin again, this time more intelligently ~ Henry Ford 
 
2.1. Model Building 
The 4TVP crystal structure of an HIV-1 BG505.SOSIP protomer (Pancera et al., 2014) was chosen as 
the template sequence to model the HIV-1 trimer (Supplementary Figure 1). This choice was made 
because BG505.SOSIP is the leading Env immunogen, and because it allowed comparison with the 
results presented in Cao et al. (2017).  Since the available structures of HIV-1 Env have missing 
structural information, such as in the gp41 region, multiple PDB files were used so that the structural 
information could be supplemented from additional files when it was not present in 4TVP; for example 
inclusion of the 5FUU structure (Lee, Ozorowski and Ward, 2016) was important for the gp41 
structural information, which was missing in other files. Additionally, it was important to include the 
4NCO trimer (Julien, Cupo, et al., 2013) in order to model a trimer rather than a monomer. The 
trimerised constructs of 4TVP  and 2B4C  were also included, though these were inferred, rather than 
directly taken from a trimeric crystal structure as with 4NCO. Thus, PDB IDs 2B4C (Huang et al., 
2005), 4TVP (Pancera et al., 2014), 4NCO (Julien, Cupo, et al., 2013) and 5FUU (Lee, Ozorowski 
and Ward, 2016) were used as structural templates in order to produce a complete model of the HIV-
1 Env ectodomain. (Structures available from: http://www.rcsb.org/.) While the fidelity of these 
structures is reliant on the quality of crystallisation experiments, using multiple templates allows a 
degree of averaging across extreme (and biologically questionable) variations; furthermore, Env is a 
dynamic molecule and the structures formed by the modelling software present atomically (and likely 
biologically) viable alternative conformations of the glycoprotein. 
After aligning the 4TVP template sequence (Pancera et al., 2014), and the 2B4C (Huang et al., 2005), 
4TVP (Pancera et al., 2014), 4NCO (Julien, Cupo, et al., 2013) and 5FUU (Lee, Ozorowski and Ward, 
2016) sequences using SeaView (Gouy, Guindon and Gascuel, 2010), the theoretical structure of the 
HIV-1 trimer was computationally modelled using Modeller 9.18 (Šali and Blundell, 1993). Modeller 
9.18 works by creating statistical models that fulfil the restraints imposed by the alignment of provided 
structures, and, thus, for each modelling run the generated models differ slightly in their 
conformations. In order to assess multiple conformations of the theoretical model for optimal 
glycosylation, Modeller was run ten times to produce ten models.  
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2.2. Computational Glycosylation  
The ten models were duplicated, and one set of ten uniformly glycosylated with Man9 glycans at every 
PNGS2 (Table 1, Figure 5A).  The second set of ten was glycosylated with a mix of Man5 glycans, 
Man9 glycans, and bi-antennary sialylated complex glycans (Complex-glycans), to form mixed-glycan 
trimers3 (Table 1, Figure 5B). The Glycam condensed notation for each glycan used can be found in 
Table 1.  
Table 1: Glycans used for computational glycosylation, in abbreviated and expanded forms 
Abbreviation Glycam Condensed Notation4 
Man9 DManpa1-2DManpa1-6[DManpa1-2DManpa1-3]DManpa1-6[DManpa1-
2DManpa1-2DManpa1-3]DManpb1-4DGlcpNAcb1-4DGlcpNAcb1-OH 
Man5 DManpa1-6[DManpa1-3]DManpa1-6[DManpa1-3]DManpb1-
4DGlcpNAcb1-4DGlcpNAcb1-OH 
Complex-glycan DNeup5Aca2-6DGalpb1-4DGlcpNAcb1-2DManpa1-6[DNeup5Aca2-
6DGalpb1-4DGlcpNAcb1-2DManpa1-3]DManpb1-4DGlcpNAcb1-
4DGlcpNAcb1-OME 
 
For the purposes of characterising the glycans in this thesis, each terminal end (apart from the end 
attached to the protein) describes a branch: thus, the Man9 and Man5 glycans have three branches, and 
the Complex-glycan has two branches (Figure 5B). The glycans are further characterised by their 
length, taken at the longest point, and counted using the distinct levels of sugar residues in the 
schematics (Figure 5B). Thus, the Man9 glycan is six sugar residues long, the Man5 glycan is five 
sugar residues long, and the Complex-glycan is seven sugars long. These characteristics are used in 
combination with the schematic depictions in order to better describe and understand the influence of 
the different glycans on the dynamics of Env.  
Glycan structures were downloaded from Glycam-Web (Woods Group, 2005), and a prototype tool 
under development for the Glycam-Web suite of tools was used to computationally attach each glycan 
to particular amino acids of the protein structures generated by Modeller 9.18 (Šali and Blundell, 
1993); this was done by exploring different torsional angles (Petrescu et al., 2004) and rotating the 
glycan to avoid clashes with other parts of the protein or adjacent glycans (software provided by Dr 
                                                 
2 These models are henceforth referred to as “Man9-Trimers”. 
3 Henceforth referred to as “Mixed-Trimers”. 
4 See http://glycam.org/docs/custombuilders/condensed-notation/  
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Oliver Grant; personal communication). A caveat of this method is that it does not consider every 
possible angle and position and thus future advancements may improve the computational 
glycosylation process. However, the glycan shield is so variable that the computational trimers that 
were generated still reflect what has been found biologically through mass spectrometry experiments 
(Cao et al., 2017, 2018; Yu et al., 2018). Thus, even though glycans were not added to every PNGS, 
there is no reason to assume that each PNGS of a particular Env glycoprotein is always glycosylated, 
which is an important, and often overlooked, point to remember in all glycosylation studies.  
The glycosylation patterns of HIV-1 Env trimers are extremely heterogeneous (See Section 1.4) 
(Pritchard, Harvey, et al., 2015) and thus the representation chosen for the Mixed-Trimer in this study 
was based on a broad classification of glycans in an attempt to limit this heterogeneity. A small mix 
of well described glycans that are known to be present on different isolates was used. 
Figure 5: Differential glycosylation of trimers 
A and B: Glycosylated trimers of (A) Man9-Trimer, and (B) Mixed-Trimer. Man9 glycans (green), Man5 glycans (blue), and 
Complex-glycans (purple) and related CFG notation of each glycan are shown, and monomers are differentiated by shades 
of green. C: Proportion of glycan types found using mass spectrometry for every PNGS on the BG505 SOSIP trimer, adapted 
from Cao et al. (2017). The x-axis depicts PNGS positions labelled according to the reference sequence, HXB2, and the y-
axis shows the proportion of the total glycans. D: The glycoform at each PNGS of the Mixed-Trimer, along with HIV-1 Env 
constant (C1-C5), variable (V1-V5) and gp41 ectodomain regions (not to scale).  
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Those sites that have been shown by MS studies to be mainly occupied by high mannose glycans were 
represented using a Man9 glycan. Sites that had a mix of high mannose, hybrid and complex glycans 
were represented by Man5, to indicate the intermediate levels of processing. Sites that were found to 
be occupied by complex glycans were represented by the Complex-glycan (Table 1). The type of 
complex glycan that was chosen represents a large, branched glycan that has been described in previous 
mass spectrometry results with both a fucosylated and unfucosylated core (Behrens et al., 2016; 
Stewart-Jones et al., 2016).  
The specific glycans added to each PNGS of the Mixed-Trimer (Figure 5D, Table 2) were defined 
according to the information found in three recent papers (Behrens et al., 2016; Panico et al., 2016; 
Cao et al., 2017). The information from Cao et al. (2017) was used to make a broad differentiation 
between high mannose and complex glycans (Figure 5C), while the data from Behrens et al. (2016) 
and Panico et al. (2016) was used to provide consensus on variable sites, such as site 355, where an 
almost equal proportion of oligomannose/hybrid and complex glycans was observed (Figure 5C) (Cao 
et al., 2017); and to distinguish the level of processing, for example at site 197, which was assigned a 
Man5 glycan given the information in Behrens et al. (2016) and Panico et al. (2016). Where there was 
not enough information, or conflicting information, such as at site 406, a Man9 glycan was added to 
that site as the default. 
As mentioned in Section 2.1, the ten models produced by Modeller 9.18 (Šali and Blundell, 1993) each 
differed slightly in their protein conformations, and accordingly, the number of glycans, out of the 84 
available PNGSs, added to each model varied due to different clashes and spatial availability. This is 
similar to what we would expect in vivo, where variable glycosylation occurs (Yu et al., 2018). Since 
the focus of this study was to compare the glycan-glycan interactions, the trimer model with the highest 
number of successfully glycosylated PNGSs was taken forward to molecular dynamics. As the 
underlying protein structure of the MD models was the same, the only differences were in their glycan 
shields; 80 glycans were successfully added to the final Man9-Trimer, and 79 to the final Mixed-
Trimer.  
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Table 2: Glycoforms at each PNGS on the Man9-Trimer and Mixed-Trimer 
HXB2 Sequence 
Number 
Glycoform in Man9-
Trimer 
Glycoform in Mixed-
Trimer 
88 Man9 Man9 
133 Man9 Man9 
137 Man9 Complex 
156 Man9 Man9 
160 Man9 Man9 
185e Man9 Complex 
185h Man9 Complex 
197 Man9 Man5 
234 Man9 Man9 
262 Man9 Man9 
276 Man9 Man5 
295 Man9 Man9 
301 Man9 Man9 
332 Man9 Man9 
339 Man9 Man9 
355 Man9 Man5 
363 Man9 Man9 
386 Man9 Man9 
392 Man9 Man9 
398 Man9 Man9 
406 Man9 Man9 
411 Man9 Man9 
448 Man9 Man9 
462 Man9 Complex 
611 Man9 Complex 
618 Man9 Complex 
625 Man9 Man9 
637 Man9 Man5 
 
2.3. System Preparation 
The two final glycosylated trimers were set up in separate MD systems using the AMBER 14 
simulation package (Case et al., 2014). The ff14SB (Maier et al., 2015) and GLYCAM_06-j1 
(Kirschner et al., 2008) force fields were used to describe the forces of attraction and repulsion for 
protein and glycan atoms, respectively. The glycoproteins were computationally immersed in 
octahedral water boxes with a 15 Å buffer using the TIP5P explicit water model (Mahoney and 
Jorgensen, 2000), and Na+ and Cl- ions were added to neutralise the systems. Prior to solvation, the 
system sizes were 48 618 atoms for the Mixed-Trimer and 49 197 atoms for the Man9-Trimer. The 
final system sizes were 660 755 atoms for the Mixed-Trimer and 635 661 atoms for the Man9-Trimer. 
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2.4. Molecular Dynamics Simulations 
The AMBER 14 Molecular Dynamics package (Case et al., 2014) was used for simulations. With the 
glycoprotein restrained at alpha-carbon atoms by a 5.0 kcal/mol force, energy minimisation was carried 
out using the steepest descent method for 10 000 cycles, followed by the conjugate gradient method 
for another 10 000 cycles. Restraints were maintained for the first equilibration step where pressure 
was kept constant and, using Langevin dynamics, the system was heated to 300 K (NPT). A second 
equilibration was performed, keeping both temperature and pressure constant (NVT), and releasing 
the positional restraints in order to relieve bad contacts. Finally, simulations of 500 ns were produced 
for each system, using a 2 femtosecond (2 x 10-15 second) time step. At the onset of this project, 500 
ns was the longest simulation in publication (Stewart-Jones et al., 2016; Zhou et al., 2017), and served 
as a useful standard for a suitable simulation length to aim for in the present study.  
2.5. Analysis 
The CPPTRAJ  analysis program (Roe and Cheatham, 2013) from the AMBER package (Case et al., 
2014) was used to calculate the root mean squared deviation (RMSD), root mean squared fluctuation 
(RMSF), and the number of hydrogen bonds for each simulation.  
Further hydrogen bond analysis was carried out using a combination of Python3 scripts, particularly 
the functions available in the Pandas module (McKinney, 2010), and Linux command line tools. The 
number of bonds between pairs of glycans was calculated (Supplementary Methods A); from this, 
hydrogen bonds and glycans that are important to maintaining the glycan shield, or differed 
substantially between the trimers (Supplementary Methods B), as well as their corresponding regions 
on the trimer (Supplementary Methods C) could be identified. Hydrogen bonding longevity was 
analysed by the percentage presence or absence of a bond over the simulation (Supplementary Methods 
D), and glycans that were present in hydrogen bonds for the greatest time were identified 
(Supplementary Methods E). Finally, by filtering the results from the previous hydrogen bond 
methods, interprotomer interactions, and differences in hydrogen bonding according to glycoform 
could be investigated.  
CPPTRAJ (Roe and Cheatham, 2013) was used to take snapshots of the simulations at 5 ns intervals, 
which were used for solvent, antibody and enzyme accessible surface area (SASA, AbASA, EASA) 
analyses with Naccess (Hubbard and Thornton, 1993), each described in more detail below. 
In order to investigate the impact of the different glycoforms on accessible surface area, the difference 
between the accessible surface areas of a glycosylated trimer (Man9-Trimer or Mixed-Trimer) and the 
same trimer with its glycans removed, was calculated for each snapshot. A probe of radius 10 Å, as 
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approximation of an antibody loop (Lemmin et al., 2017), was used to calculate the AbASA, and for 
the SASA, a probe of radius 1.4 Å (commonly accepted as the radius of water) was used. The ten 
protein residues with the largest median change in accessible surface area between the glycosylated 
and de-glycosylated forms were plotted for each trimer. 
2.6. Investigating EASA and SASA as Proxies for Glycan Processing 
Since determining the level of glycan processing from MS results is a costly and time-consuming 
process which relies heavily on biosynthetic assumptions, the secondary aim of this project was to 
explore a computational method for determining whether a Man9 glycan will be processed. In its 
biological context, Man9 is processed by ER Man I, and it is known that glycan-dense regions where 
enzymes cannot fit are left underprocessed (See Section 1.4). 
Thus, the accessible surface area to ER Man I was investigated using Naccess (Hubbard and Thornton, 
1993). In order to determine the probe size, the mechanism of ER Man I was taken into account; as a 
barrel shaped enzyme, only one side needs to fit between glycans for processing to occur. Accordingly, 
one side of ER Man I (PDB 1X9D) (Karaveg et al., 2005) was measured in UCSF Chimera (Pettersen 
et al., 2004) and from this it was determined that a probe of 13 Å should be used for the Naccess 
calculations. These calculations were carried out on the Man9-Trimer, since the Man9 glycan 
accessibility both in the ER and after oligomerisation and translocation to the Golgi apparatus is 
believed to influence glycan processing (Doores et al., 2010). Since ER Man I removes one mannose 
residue at a time, the EASA value of the terminal (0MA) glycan residues were filtered from the 
Naccess results and binned according to the corresponding processed glycoform of each site on the 
Mixed-Trimer – i.e. Man9, Man5, or Complex-glycan (See Supplementary Methods F). The 
distributions were plotted as boxplots using Matplotlib (Hunter, 2007), and statistically analysed for 
differences using the Mann-Whitney U test.  
In addition to exploring the use of EASA in this context, the commonly used SASA metric was 
investigated, since this has been linked to the level of glycan processing (Suga, Nagae and Yamaguchi, 
2018), and thus would be useful to compare. Using a probe of radius 1.4 Å, the SASA of the terminal 
(0MA) glycan residues was calculated, binned, plotted, and analysed for differences as above.  
2.7. Graphing and Visualisation 
UCSF Chimera (Pettersen et al., 2004) was used for molecular visualisation. Flourish (Kiln Enterprises 
Ltd, 2016), xmgrace (Turner, 1991; Stambulchik, 1998), Matplotlib (Hunter, 2007), R (Ihaka and 
Gentleman, 1996), and Microsoft Excel were used to make the various graphs.  
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2.8. Statistical Analyses 
Statistical analyses were carried out in Python3 using the SciPy module (Jones et al., 2001). The Mann-
Whitney U test was chosen due to the skewed distributions of the data, as well as its ability to be used 
with unequal sample sizes.   
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3. Results 
The facts are always friendly. Every bit of evidence one can acquire, in any area, leads one that 
much closer to what is true ~ Carl Rogers 
 
Molecular dynamics is a commonly used approach to study glycans and glycoproteins since these 
molecules are difficult to study in the laboratory (See Section 1.5.4). In the case of the heavily 
glycosylated HIV-1 envelope protein, this method has been used with a set of uniform glycans in 
multiple studies (See Section 1.5.4); however this does not fully reflect the diversity of the glycan 
forms seen on the native virion (See Section 1.4). 
In order to expand on previous work, two models were simulated, using molecular dynamics, and 
compared: a uniformly glycosylated Man9-Trimer and a more diversely glycosylated Mixed-Trimer 
(See Section 2.2). The primary aim was to investigate the impact of the different glycoforms on the 
dynamics of the protein. Sections 3.1 to 3.5 of the Results address this question. The secondary aim 
was to explore whether a computational approach to predicting the level of glycan processing could 
be proposed. This is addressed in Section 3.6 of this chapter.   
3.1. Glycan Occupancy: Assessing the impact of glycoforms on glycan occupancy 
Ten HIV-1 Env trimer models were computationally generated using Modeller 9.18 (Šali and Blundell, 
1993) in order to find the optimal conformation for maximal glycosylation.  
In order to determine the acceptability of the models, they were assessed by their Discrete Optimised 
Protein Energy (DOPE) scores, where a lower score indicates a more native-like conformation (Shen 
and Sali, 2006); and by their GA341 scores, which indicate the match between the sequences within 
the range of 0 (no match) and 1 (complete match) (Melo, Sánchez and Sali, 2002; John and Sali, 2003). 
All models had DOPE scores of -204 000 or lower, and GA341 scores of 1. 
The ten models were duplicated, and one set of ten was glycosylated with Man9 glycans only, while 
the other set of ten was glycosylated with a mix of Man9, Man5, and Complex-glycans (See Section 
2.2).  
There are 84 PNGSs distributed unevenly across the HIV-1 trimer sequence used in this work, with 
the highest concentrations in the V1/V2 and V4 regions (Figure 5D, Supplementary Figure 1). While 
the protein structure does affect glycan occupation, since the ten models used for glycosylation were 
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the same for both the Man9-Trimers and the Mixed-Trimers, differences in the percentage glycan 
occupation can be attributed specifically to the differences in the types of glycans.  
The Man9-Trimer was glycosylated uniformly with Man9 glycans; these have three branches (tri-
antennary), and are six sugars long. As well as Man9 glycans, the Mixed-Trimer also contained Man5 
glycans, which are tri-antennary, five sugar long glycans, and Complex-glycans, which are bi-
antennary, seven sugar long glycans (See Section 2.2). Thus the volume occupied by each of these 
glycoforms differs according to their composition; this in turn affects the possibility for glycan 
occupancy at any given PNGS.  
Major differences in glycan occupation between the Man9-Trimer and the Mixed-Trimer were 
observed at two PNGSs: 185h, and 392 (Figure 6A and B). Unsurprisingly, since the glycan at site 
185h is a Complex-glycan on the Mixed-Trimer, it was added less frequently than on the Man9-Trimer. 
Conversely, the glycan at site 392 is added less frequently on the Man9-Trimer; while a Man9 glycan 
is present at this site on both trimers, the surrounding glycans on the Mixed-Trimer are Man5 glycans, 
allowing extra space, and thus higher occupancy, on this model compared to the Man9-Trimer.  
Furthermore, site 185h falls into the V1/V2 region of the HIV-1 Env trimer, while site 392 falls into 
the V4 region, close to the CD4-binding site. Both regions are densely glycosylated, which may result 
in greater competition for space in these regions.  
After duplicating the models and glycosylating each set with either Man9 glycans or a mix of glycans, 
the Man9-Trimer and Mixed-Trimer with the most glycans were taken forward for the rest of the 
Figure 6:  Percentage glycan occupation at each PNGS across ten models 
A: Percentage glycan occupation of each PNGS. Two PNGSs of interest, at sites 185h and 392, are starred (*) to indicate 
where the glycan occupation differs between the Man9-Trimer and the Mixed-Trimer. B: Glycosylated trimer illustrating 
the clustering of glycans 185h (pink) and 392 (orange), in 3D, rather than linear, space. The CD4-binding site is show in 
blue for structural context.  
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analysis. Out of 84 PNGSs, the Man9-Trimer had 80 N-linked glycans and the Mixed-Trimer had 79 
N-linked glycans. The absent glycans were distributed across the different protomers (Table 3). 
Table 3: Potential N-glycosylation sites that were not glycosylated on the final models 
Man9-Trimer Mixed-Trimer 
392 (Protomer 1) 386 (Protomer 1) 
363 (Protomer 2)  462 (Protomer 1) 
392 (Protomer 2) 185h (Protomer 2) 
363 (Protomer 3) 392 (Protomer 2) 
 363 (Protomer 3) 
 
3.2. RMSD: Assessing the stability of simulations 
The root mean squared deviation (RMSD) of the protein backbone atoms was calculated relative to 
the first frame for each of the trimers using CPPTRAJ (Roe and Cheatham, 2013) to assess the stability 
of the simulations (Figure 7). The RMSD represents the overall movement of the molecule at every 
time point in the simulation.  
Figure 7: Graph to compare RMSD of the Mixed-Trimer and Man9-Trimer 
RMSD (Angstrom) of the Man9-Trimer (green) and Mixed-Trimer (purple). The steep upward gradient represents the burn-
in time (shaded orange). Each frame represents 2 femtoseconds (fs; 2 x 10-15 seconds) of simulation out of a total of 500 ns 
of simulation. The included subplot shows boxplots depicting minimum, lower quartile, mean (dotted line), median, upper 
quartile, and maximum of the RMSD for the Man9-Trimer and Mixed-Trimer (burn-in removed). Points depict outliers.  
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The steep ascent at the beginning of the graph represents the “burn-in” time, where the molecules are 
still equilibrating, and a burn-in time of 10ns was removed prior to further analysis of the simulations 
(Figure 7, shaded orange). The median RMSD values for the Man9-Trimer and the Mixed-Trimer were 
3.67 Å and 3.58 Å, respectively. For a large proportion of the simulation (64%), the RMSD of the 
Mixed-Trimer backbone was lower, and less fluctuating, than that of the Man9-Trimer, indicating a 
slightly more stable protein form within the Mixed-Trimer simulation. 
 
3.3. RMSF: Investigating the effect of different glycans on protein stability  
The root mean squared fluctuation (RMSF) of the alpha-carbon atoms of each protein residue in the 
trimer was calculated using CPPTRAJ (Roe and Cheatham, 2013) and is a measure of how much each 
residue moves relative to the average structure over the course of the simulation (Figure 8).  
There are notably higher fluctuations towards the beginning of the gp41 protein chains in the first and 
third protomers, which may represent a confounding factor that should be improved upon by adding 
greater restraints on these residues in future studies. The outlying RMSF values caused by this issue 
Figure 8: Comparison of RMSF for Mixed-Trimer and Man9-Trimer 
RMSF was calculated per protein residue for each trimer to investigate whether the different glycoforms affected protein 
stability. Protomer divisions, as well as gp120 and gp41 distinctions are indicated above the graph. HIV-1 regions are shown 
by alternating blocks of blue (constant regions) and light grey (variable regions) for gp120, and dark blue for gp41. This is 
enlarged at the bottom of the figure for readability.  
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were excluded for statistical analysis, and only RMSF values greater than or equal to 6.7 were included 
(Supplementary Table 1). 
The median RMSF values for the Man9-Trimer and Mixed-Trimer were 1.25 Å and 1.15 Å 
respectively. The Man9-Trimer exhibited higher RMSF 55% of the time, indicating a more fluctuating 
protein backbone in the Man9-Trimer than in the Mixed-Trimer.  This corresponds to the findings 
from the RMSD analysis. 
Similar patterns of stability were present across the protomers. Local maxima corresponded to variable 
loops, with the V4 and V5 regions having the most pronounced fluctuations. Thus, variable regions 
had a greater range of movement than the constant regions – with the exception of the start of the C1 
region.  The high fluctuations in the first residues of the C1 regions may be due to the lack of sufficient 
restraint at the ends of the gp120 subunits. 
  
3.4. Hydrogen Bonds: Investigating interactions in the glycan shield 
3.4.1. Quantifying the glycan interactions from simulations 
In order investigate the differences in the glycan shields themselves (rather than just the underlying 
proteins), hydrogen bond analysis was carried out on the simulations using CPPTRAJ (Roe and 
Cheatham, 2013).  
A hydrogen bond is defined as an interaction between a hydrogen bond donor (X-H) – that is, a 
hydrogen bound to an electronegative atom (such as oxygen, fluorine, or nitrogen) – and a hydrogen 
bond acceptor (X: ), where an atom contains a lone pair of electrons.  
In order to quantify the glycan interactions, the number of hydrogen bonds between every interacting 
glycan pair was calculated, e.g. between glycan 133 of Protomer 1 (1_133_m9) and glycan 137 of 
Protomer 1 (1_137_m9/c)5. Only the interactions with other glycans were included for this count; intra-
glycan interactions were specifically excluded (Supplementary Methods A).  
                                                 
5 This notation will be used to refer to glycans in figures and tables in the rest of the thesis: 1_133_m9 refers to protomer 
1, glycan 133, with m9, which is a Man9 glycan. The notation m5 is used to denote Man5 glycans, e.g. 1_197_m5, and c 
is used to denote Complex-glycans, e.g. 1_137_c. Where the same glycan takes on different glycoforms in the two trimers 
and is being discussed in a general manner, both glycoforms will be included, e.g. 1_137_m9/c refers to glycan 137 of 
protomer 1, which is a Man9 glycan in the Man9-Trimer, and a Complex-glycan in the Mixed-Trimer. The specific 
inclusion of the glycoform whenever a glycan is referred to is to aid the reader in following the respective types of glycans, 
which change between the two trimers.  
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The Mixed-Trimer had a total of 1 332 406 hydrogen bonds over the course of the simulation, 24.8% 
more than the Man9-Trimer, where 1 067 251 hydrogen bonds occured. By counting the number of 
lone pairs and hydrogens bound to electronegative atoms, the total number of hydrogen bonds possible 
over the simulation (if all potential hydrogen bond donors and acceptors were involved at every frame) 
was coarsely determined in order to obtain estimates for the Mixed-Trimer and Man9-Trimer (Table 
4). The maximum for the Man9-Trimer was estimated to be 66 640 000 potential hydrogen bonds, 
whereas 61 691 000 potential hydrogen bonds were estimated for the Mixed-Trimer. By this 
calculation, the Man9-Trimer has the potential to form 8% more hydrogen bonds than the Mixed-
Trimer. Thus, the observation here, where the Man9-Trimer had substantially less hydrogen bonds 
present across the simulation than the Mixed-Trimer, is remarkable.  
Table 4: Potential for hydrogen bonds 
Glycan type Hbond acceptors 
X: 
Hbond donors 
X-H 
Count for 
Man9-Trimer 
Count for 
Mixed-Trimer 
Man9 112 34 80 51 
Man5 72 22 0 12 
Complex-glycan 128 36 0 16 
Total potential Hbonds in 1 frame:* 2720 2518 
Total potential Hbonds across simulation (24500 frames):  66 640 000 61 691 000 
*The total potential hydrogen bonds were calculated based on the number of Hbond donors, since this is the limiting factor.  
 
On the Man9-Trimer, two sets of hydrogen bonded glycan pairs (glycans 88 and 625 on Protomer 3, 
and glycans 295 and 332 on Protomer 1) (Figure 9A, Supplementary Figure 2) made up 12.8% of its 
overall hydrogen bonding. The Mixed-Trimer on the other hand had a more distributed hydrogen bond 
count across interactions, with 8% more individual bonds making up the total hydrogen bond count. 
The two glycan pairs with the highest hydrogen bond count on the Mixed Trimer (Man9 glycans 262 
and 448 on Protomer 1, and the 234 Man9 glycan and 462 Complex-glycan on Protomer 2) made up 
7.4% of the total hydrogen bonding.  
Each glycan bonding pair contained two glycans, and a number of glycans were involved in multiple 
interactions. Due to this finding, bonding pairs were divided into their component glycans in order to 
determine which glycans formed the largest number of hydrogen bonds over the course of the 
simulation, e.g.  the interaction of 72 361 hydrogen bonds between glycans 295 and 332 of Protomer 
1 of the Man9-Trimer would result in 72 361 being added to the total contribution by glycan 295, as 
well as that of glycan 332 (Supplementary Methods B).  
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Figure 9: Comparison of inter-glycan hydrogen bonding for the Man9-Trimer and Mixed-Trimer 
A: Chord diagrams of glycan-glycan hydrogen bond counts ≥5000 coloured according to glycoform in Mixed-Trimer and repeated 
across protomers. Green to yellow range = Man9, blue range = Man5, Purple range = Complex-glycans. Each chord joins 2 glycans 
and its width corresponds to the total number of hydrogen bonds present between those glycans across the simulation. B: Glycan 
percentage contribution to overall hydrogen bonding. Blue (0%) to yellow (4%). Individual percentages and hydrogen bonding counts 
by glycan can be found in Supplementary Table 2.  
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The hydrogen bond contribution for every glycan was converted into a percentile in order to allow 
comparison between the trimers (Figure 9B, Supplementary Table 2). In this way, the glycans that 
were most involved in hydrogen bonding could be identified.  This allows us to see not only which 
bonds played an important part in stabilising the glycan shield, but which individual glycans too.  
On the Man9-Trimer, it can be seen that the glycans involved in the two dominant hydrogen bonds 
(glycans 332 and 295 of Protomer 1, and 625 and 88 of Protomer 3) also had the largest contribution 
to the overall hydrogen bonding in the glycan shield (Figure 9B, Supplementary Table 2). 
This was not the case for the Mixed-Trimer, where the glycans that contributed most to the hydrogen 
bonding were involved in numerous different bonding pairs, e.g. the Complex-glycan at site 137 of 
Protomer 1 of the Mixed-Trimer had a total of 91 363 hydrogen bonds – including 43 870 bonds with 
Man9 glycan 133 of Protomer 1, 24 574 with Complex-glycan 185e of Protomer 1, 13 899 with Man9 
glycan 156 of Protomer 1, and 7 227 bonds with Complex-glycan 185e of Protomer 2, as well as minor 
bonds with other glycans (Figure 9A, Supplementary Figure 3). The two highest contributors to 
hydrogen bonding on the Mixed-Trimer were Complex-glycans.  
Symmetry across the protomers did not exist when it came to identifying individual glycans that 
consistently formed hydrogen bonds with surrounding glycans, e.g. while the Complex-glycan 137 on 
Protomer 1 of the Mixed-Trimer had a high hydrogen bond count and contributed 3.4% of the total 
hydrogen bonding, the same glycan on Protomers 2 and 3 only contributed 1.6% and 1.4% 
respectively. This non-symmetrical sharing of hydrogen bonds between protomers was seen on both 
the Man9-Trimer and the Mixed-Trimer.  
The apex glycans contributed to the hydrogen bonding to a higher degree on the Mixed-Trimer, where 
they made up about a fifth of the total, compared to the apex glycans on the Man9-Trimer, where they 
accounted for less than a third of the total hydrogen bonding (Figure 9B). On the Mixed-Trimer, these 
glycans at the apex were predominantly Complex-glycans.    
3.4.2. Assessing how glycan-glycan hydrogen bonds cluster into the defined regions of HIV-1 Env 
In order to investigate if hydrogen bonds were more likely to form across specific regions of the HIV-
1 trimer, the total number of glycan-glycan hydrogen bonds was determined for the variable (V1-V5) 
loops and constant (C1-C5) regions of gp120, as well as for gp41 (Supplementary Methods C). 
Heatmaps were then plotted to show regions with higher hydrogen bond interactions within each trimer 
(Figure 10A and B).  
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It is likely that areas with a high density of glycans, or glycans in close proximity, would interact the 
most. Thus, the major diagonal ascending from left to right (Figure 10A and B), where each protomer 
of the trimers is interacting within itself, is unsurprising. Instead, it is in the further details that 
interesting differences between the trimers can be seen.  
 
Figure 10: Comparing glycan-glycan hydrogen bonds by HIV-1 region 
Individual hydrogen bonds were allocated to their respective HIV-1 regions to investigate which regions were most involved 
in hydrogen bonding. A and B: Heatmaps of the Man9-Trimer (A) and Mixed-Trimer (B) showing hydrogen bonding between 
HIV-1 regions. Grid used to represent protomer divisions. Main diagonal shows intra-protomer interactions. Note: The Mixed-
Trimer heatmap does not contain the V5 region in Protomer 1 as the only glycan in this region was not added during 
glycosylation (Table 3). Neither heatmap contains the C5 region as it does not contain any glycans. C and D: 3D depictions of 
HIV-1 regions of high hydrogen bonding involvement in (C) the Man9-Trimer, and (D) the Mixed-Trimer. Notable regions of 
high hydrogen bonding are highlighted according to the colours of the highest count for these regions in their respective 
heatmaps.  
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The most notable hydrogen bonding occurred in the glycan-dense V1/V2 region of Protomer 1 of the 
Mixed-Trimer, where there was a total of 140 785 intra-region hydrogen bonds (Figure 10B and D, 
highlighted in yellow). In addition, the V1/V2 region of Protomer 3 of the Mixed-Trimer included a 
remarkable number of intra-region hydrogen bonds, totalling 75 748 bonds (Figure 10B and D, 
highlighted in turquoise).   
Similarly, the V1/V2 regions of Protomers 1 and 3 of the Man9-Trimer formed comparable levels of 
intra-region hydrogen bonding to the V1/V2 region of Protomer 3 of the Mixed-Trimer (Figure 10A 
and C, highlighted in turquoise). Intriguingly, the C2 and C3 regions of Protomer 1 also interacted 
with each other to a comparable level (Figure 10A and C, highlighted in turquoise); this was the most 
notable inter-region hydrogen bonding in either trimer.  
Interestingly, for both trimers, one protomer (Protomer 2 for the Mixed-Trimer and Protomer 3 for the 
Man9-Trimer) formed substantially less hydrogen bonds within its V1/V2 region compared to the other 
two protomers (Figure 10A and B).  
In contrast to the high levels of hydrogen bonding formed by the glycan-dense V1/V2 region, the V4 
region, which is also glycan-dense, did not form an exceptional level of hydrogen bonds.  
Outside of the main diagonal of the heatmaps, we see a distinct difference in interprotomer hydrogen 
bonding between the two trimers (Figure 10A and B). The Mixed-Trimer formed interprotomer 
hydrogen bonds mainly between V1/V2 regions, with each protomer interacting substantially with 
every other protomer. In contrast, the Man9-Trimer formed interprotomer interactions between the C2 
and V1/V2, V1/V2 and V1/V2, and C2 and V3 regions of Protomers 1 and 3, as well as interactions 
between the V1/V2 and C2 regions of Protomers 2 and 3. Interestingly, the Man9-Trimer exhibited 
hardly any hydrogen bonds between Protomer 1 and 2, totalling 3 158 interprotomer bonds between 
all regions of these protomers. While the V1/V2 region was involved in the interprotomer interactions 
on both trimers, the interactions between the V1/V2 loops were more pronounced on the Mixed-Trimer 
than on the Man9-Trimer, with 150 246 and 33 575 hydrogen bonds respectively.  
3.4.3. Investigating differences in interprotomer hydrogen bond interactions 
Due to the marked differences in interprotomer interactions between the Man9-Trimer and the Mixed-
Trimer, this subset of hydrogen bonds was further investigated, in order to examine the specific glycans 
and glycan bonding pairs involved.  
The Mixed-Trimer had a total of 177 778 interprotomer hydrogen bonds, which is nearly double the 
96 551 interprotomer hydrogen bonds found on the Man9-Trimer. These interprotomer numbers 
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translate to 13.3% and 9% of the total number of hydrogen bonds in the glycan shields of the Mixed-
Trimer and Man9-Trimer respectively. Four dominant interprotomer interactions (with a count of 5000 
or more hydrogen bonds) were identified for the Man9-Trimer and ten dominant interprotomer 
interactions were identified for the Mixed-Trimer (Figure 11A, Table 5).  
The range of magnitudes of hydrogen bonding between glycan bonding pairs of the dominant 
interactions was remarkable in its difference between the trimers: the Man9-Trimer had a narrow 
range, between 11 844 and 26 006 bonds, while the Mixed-Trimer had a wide range, between 6031 
and 39 730 bonds (Table 5).  
The dominant interprotomer interactions represented 82.1% and 83.4% of the total interprotomer 
interactions for the Man9-Trimer and Mixed-Trimer respectively, with minor interactions (those with 
a count of less than 5000 hydrogen bonds) making up the remaining 17-18%. Of significant interest 
was the observation that eight of the ten dominant interprotomer interactions on the Mixed-Trimer 
involved Complex-glycans (Table 5).  
Interestingly, the Complex-glycan 185e on Protomer 2 of the Mixed-Trimer appears to fill in for an 
adjacent missing Complex-glycan at position 185h on this protomer (Table 3; Figure 11B). However, 
the Complex-glycans at position 185e of the other two protomers, where the glycan at position 185h 
is present, are not involved in the dominant interprotomer interactions (Figure 11A).  
Table 5: Dominant interprotomer interactions for the Man9-Trimer and Mixed-Trimer (≥5000) 
Man9-Trimer Mixed-Trimer 
Interaction 
Number of 
Hydrogen bonds 
Interaction 
Number of Hydrogen 
bonds 
2_156_m9 - 3_197_m9 26 006 2_160_m9 - 3_185h_c 39 730 
1_185h_m9 - 3_160_m9 25 757 1_185h_c - 2_185e_c 25 400 
1_197_m9 - 3_301_m9 15 646 1_156_m9 - 2_185e_c 22 756 
1_197_m9 - 3_156_m9 11 844 1_160_m9 - 3_160_m9 13 844 
  2_301_m9 - 3_197_m5 10 696 
  1_185h_c - 3_160_m9 9 585 
  1_137_c - 2_185e_c 7 227 
  1_160_m9 - 2_185e_c 6 834 
  1_185h_c - 3_185h_c 6 187 
  2_618_c - 3_611_c 6 031 
Total 79 253 Total 148 290 
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Figure 11: Comparison of interprotomer hydrogen bonding of the Man9-Trimer and Mixed-Trimer 
A: Chord diagrams of interprotomer glycan-glycan hydrogen bond counts ≥5000 coloured according to glycoform of the Mixed-
Trimer and repeated across protomers. Green to yellow range = Man9, blue range = Man5, Purple range = Complex-glycans. Each 
chord joins 2 glycans and its width corresponds to the total number of hydrogen bonds present between those glycans across the 
simulation. B: Top view and 3-way rotated side view of trimers showing glycans that contribute to interprotomer interactions, 
coloured according to their percentage contribution to overall hydrogen bonding in the glycan shield. Blue (0%) to yellow (4%).  
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Another striking observation was that for both trimers, the majority of interprotomer interactions were 
formed by glycans at the apex of the trimer (glycans at sites 137, 156, 160, 185e, 185h, and 301). On 
the Mixed-Trimer, the glycans present on each individual protomer interacted with the glycans on the 
other two protomers (Table 5, Figure 11A and B). Conversely, a two-way stabilisation effect was 
observed in the Man9-Trimer, where the glycans on Protomers 1 and 3, and the glycans on Protomers 
2 and 3 interacted (Table 5, Figure 11A and B). This two-way stabilisation is likely linked to the 
scissoring that was observed in the Man9-Trimer simulation, and which results in an exposed CD4 
binding site between Protomers 1 and 2, which do not interact during the simulation (Figure 12). 
 
Out of the five glycans involved in interprotomer interactions on both models (glycans at sites 156, 
160, 197, 185h, and 301), only glycans 185h and 160 formed the same interacting interprotomer pair 
on both the Man9-Trimer and the Mixed-Trimer (Table 5). These interactions were observed between 
Protomers 1 and 3, and for the Mixed-Trimer the interacting pair consisted of a Man9 glycan (site 160) 
and Complex-glycan (site 185h) (Figure 13). The Mixed-Trimer extended the list of its interprotomer 
interaction glycans to include the glycans at sites 137, 185e, 611, and 618 – all of which were Complex-
glycans (Figure 13).  
Figure 12: Scissoring of the Man9-Trimer 
This snapshot, taken at 170 ns, highlights the scissoring of the protomers on the Man9-Trimer. The red arrow indicates the 
exposed CD4 binding site between Protomers 1 and 2. Colours here were used to differentiate between neighbouring 
glycans. 
Clare Garrard, GRRCLA001 
36 
 
 
 
Figure 13: UpSet plot of common glycan sites involved in dominant interprotomer interactions 
The dominant interprotomer glycan interactions of the Mixed-Trimer and Man9-Trimer are illustrated; the set size presents 
the number of glycans from each protomer involved in the dominant interprotomer hydrogen bonding interactions; the size 
of the intersection shows the number of glycan sites common across protomers and the shaded circles (and lines) indicate 
the set of protomers where that glycan is involved in interprotomer interactions.  
 
3.4.4. Investigating hydrogen bond longevity versus strength of bonding 
Glycans interact dynamically (Stewart-Jones et al., 2016), with some forming lasting interactions over 
nanoseconds, and others interacting transiently over femtoseconds. Additionally, the number of 
hydrogen donors and acceptors differs between glycoforms and therefore the potential number of 
hydrogen bonds varies depending on the glycan pair (Table 4).  
Here, hydrogen bonds were analysed according to presence or absence in each 2 femtosecond frame 
(Supplementary Methods D). Similar to the quantification of hydrogen bonds by glycan (Section 
3.4.1), these bonds were then divided into their component glycans in order to identify the glycans that 
were most involved in hydrogen bonding over the course of the simulation (Supplementary Methods 
E).  
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Glycans that were present in hydrogen bonding pairs in more than 90% of the simulation were defined 
as predominantly present and those present in less than 10% of the simulation were defined as 
predominantly absent.  
The Man9-Trimer had five glycans that were predominantly absent from its set of glycans forming 
hydrogen bonds (Table 6). The Mixed-Trimer, on the other hand, only had one glycan that was 
predominantly absent, which was the Complex-glycan 611 on Protomer 1 (Table 6). Notably, the 
predominantly absent glycans were largely located at the base of the trimer (Figure 14A and B).  
Conversely, the Mixed-Trimer had thirteen glycans that were predominantly present in the set of 
glycans forming hydrogen bonds, while the Man9-Trimer had only seven (Table 6). Strikingly, no 
Man5 glycans were included in the predominantly present glycans on the Mixed-Trimer. The 
predominantly present glycans clustered on the Mixed-Trimer (Figure 14B), and conversely were 
dispersed on the Man9-Trimer (Figure 14A). 
 
Table 6: Glycans that were predominantly present or absent in hydrogen bonding 
Predominantly Absent Predominantly Present 
Man9-Trimer Mixed-Trimer Man9-Trimer Mixed-Trimer 
1_406_m9 1_611_c 1_185h_m9 1_133_m9 
2_197_m9  1_295_m9 1_137_c 
2_611_m9  1_332_m9 1_160_m9 
2_618_m9  1_355_m9 1_185h_c 
3_618_m9  2_625_m9 1_262_m9 
  3_88_m9 1_448_m9 
  3_625_m9 2_234_m9 
   3_160_m9 
   3_185h_c 
   3_295_m9 
   3_332_m9 
   3_411_m9 
   3_625_c 
Clare Garrard, GRRCLA001 
38 
 
3.4.5. Glycoform differences in hydrogen bonding 
Since the glycan shields from the two models used in this work are differentiated by their glycoforms, 
these were compared in the context of hydrogen bonding.  
End to end, at the longest point, the Man9 glycan is six sugars long, and it has three branches. Similarly, 
the Man5 glycan has three branches, but it is five sugars long. The Complex-glycan is seven sugars 
long and has two branches, and unlike the Man5 and Man9 glycans, it is made up of a mix of sugar 
residues, including a reactive terminal sialic acid group (See Section 2.2). Due to these differences in 
structure it was expected that differences in hydrogen bonding would be observed.  
The Man5 glycans and Complex-glycans (Figure 4) on the Mixed-Trimer were compared to the Man9 
glycans at equivalent positions on the Man9-Trimer (Table 2). Since the Man5 glycans are shorter and 
have fewer residues than the Man9 glycans, it was anticipated that the glycans at these sites would be 
less involved in hydrogen bonding on the Mixed-Trimer than on the Man9-Trimer. 
The Man5 and Man9 glycans present at sites 197, 276, 355, and 637 were involved in hydrogen 
bonding in a median of 42.4% of frames on the Man9-Trimer, compared to 34.8% of frames on the 
Mixed-Trimer. However, the difference in hydrogen bond presence between the Man5 and Man9 
Figure 14: Location of predominantly present and absent glycans in hydrogen bonding 
Hydrogen bonds were analysed according to presence or absence by frame, and the glycans present in >90% or <10% of 
the simulation were highlighted on the trimers. A: Man9-Trimer. B: Mixed-Trimer 
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glycans at equivalent sites was not significant (Mann Whitney U = 71, nman9 = nmixed = 13, p = 0.49, 
one-tailed).  
Strikingly, the glycans at position 197 of Protomers 1 and 3 of the Man9-Trimer were involved in three 
of its four dominant interprotomer interactions. These accounted for 67.5% of the dominant Man9-
Trimer interprotomer interactions (Table 7).  Conversely, for the Mixed-Trimer, the Man5 glycan at 
site 197 formed part of only one of the ten dominant interprotomer interactions (site 197 on Protomer 
3); this accounted for 7.21% of the dominant Mixed-Trimer interprotomer interactions (Table 7).  
 
Table 7: Comparison of sites where glycoforms differ 
Glycoform equivalent sites 
Man9/Man5  
equivalent glycans 
Man9/Complex 
equivalent glycans 
Trimer 
Man9-
Trimer 
Mixed-
Trimer 
Man9-
Trimer 
Mixed-
Trimer 
Total % glycan contribution to 
hydrogen bonding 
10.90% 7.50% 17.40% 25.20% 
Median percentage presence in frames 42.40% 34.80% 44.40% 74.10% 
Total hydrogen bond count 217 272 195 622 326 910 596 881 
Percentage of interprotomer bonds  
≥ 5 000 
67.50% 7.21% 32.50% 83.45% 
 
Turning to the Complex-glycans: these were added to sites 137, 185e, 185h, 462, 611, and 618 on the 
Mixed-Trimer. It was expected that the Complex-glycans would contribute more to hydrogen bonding 
than the Man9 glycans, due both to their greater length, and the presence of a reactive terminal sialic 
acid group.  
The median percentage of frames where the glycans were involved in hydrogen bonding was 44.4% 
for the Man9-Trimer, and 74.1% for the Mixed-Trimer (Table 6). This difference was significant 
(Mann Whitney U = 86, nman9 = 18, nmixed = 16, p = 0.02, one-tailed). Furthermore, the Complex-
glycans contributed 7.8% more to the overall hydrogen bonding of the Mixed-Trimer than their Man9 
glycan counterparts contributed to the hydrogen bonding of the Man9-Trimer.  
The Complex-glycans also played an important role in the interprotomer interactions on the Mixed-
Trimer, as was noted in Section 3.4.3. Compared to the glycans at the same sites on the Man9-Trimer, 
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the Complex-glycans contributed 51% more to the dominant interprotomer hydrogen bonding in the 
Mixed-Trimer. This was in contrast to the difference observed between the Man5 and Man9 glycans 
at equivalent sites, mentioned previously.  
 
3.5. Changes in Solvent and Antibody Accessible Surface Area 
In order to investigate the impact of different glycans on the accessible surface area of the trimers, the 
change in solvent accessible surface area (∆SASA) and antibody accessible surface area (∆AbASA) 
between the glycosylated and de-glycosylated forms was calculated for every residue of a Man9-
Trimer and a Mixed-Trimer at 5 ns intervals (See Section 2.5).  
Naccess (Hubbard and Thornton, 1993) was used for the accessible surface area calculations. A probe 
of radius 10Å was used to calculate the ∆AbASA (Figure 15A), since 20Å is the width of an antibody 
loop (Lemmin et al., 2017). The ∆SASA calculations were done with a probe of radius 1.4 Å as this 
approximates the size of water (Figure 15B) (See Section 2.5).  
It is worth noting that the accessible surface area changes for SASA and AbASA are in vastly different 
ranges due to the differing Gaussian surfaces that are produced in the rolling ball calculation of Naccess 
(Hubbard and Thornton, 1993) (Figure 15 A and B).  
 
The ten sites with the largest median change in SASA or AbASA were plotted for each trimer in order 
to compare how the different glycoforms affected accessible surface area, and which regions were 
most affected (Figure 16).  
Figure 15: Surfaces for antibody and solvent accessible surface area calculations 
A and B: Gaussian surfaces for (A) ∆AbASA (using a 10Å probe) and (B) ∆SASA (using a1.4Å probe) of Man9-Trimer 
(green), Mixed-Trimer (purple) and the Protein Trimer with no glycans (yellow).  
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For both the SASA and AbASA measurements, the heavily glycosylated V1/V2 and V4 regions were 
most prominently featured in the group of sites which had the highest change in their accessible surface 
area due to the addition of glycans (Figure 16A and B). The same sites repeated across protomers and 
were similar between the two trimers.  
In order to locate these sites in context of the HIV-1 Env trimer, the top ten sites of accessible surface 
area change were plotted on the Mixed-Trimer and Man9-Trimer for both the AbASA (Figure 17) and 
the SASA results (Figure 18). 
For both the Mixed-Trimer and the Man9-Trimer the top ten sites of AbASA change fell into the gp120 
subunits of the trimers. Some of these sites were occupied by glycans: for the Man9-Trimer, these 
were site 411 on Protomer 2, and sites 185h and 462 on Protomer 3; and for the Mixed-Trimer these 
were sites 185h on Protomer 2 and 462 on Protomer 3 – both of which were occupied by a Complex-
glycan. Notably, site 462 on Protomer 3 was included for both trimers. The majority of sites of highest 
AbASA change were located towards the apex of the trimers (Figure 17).  
 
Figure 16: Solvent accessible and antibody accessible surface area of protein residues 
A and B: Graphs of top ten sites of (A) ∆AbASA and (B) ∆SASA with the addition of glycans, for the two trimers. The 
majority of sites fall into the V1/V2 and V4 regions. C: Magnification of HIV-1 Env regions on x-axes of graphs A and B. 
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Figure 17: Sites of highest change in AbASA on the Man9-Trimer and Mixed-Trimer 
The ten sites with the highest ∆AbASA were plotted onto the trimers for structural context. A and C: Side view. B and D: 
Top view of the Man9-Trimer and Mixed-Trimer.  
 
Figure 18: Sites of highest SASA change on the Man9-Trimer and Mixed-Trimer 
The ten sites with the highest ∆SASA were plotted onto the trimers. A and C: Side view. B and D: Top view of the Man9-
Trimer and Mixed-Trimer.     
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Similarly, the majority of the sites with the highest change in SASA were found at the apex of the two 
trimers (Figure 18). However, unlike the sites identified in the AbASA analysis, the spread of these 
sites was distinct between the Man9-Trimer and the Mixed-Trimer: sites were located close to the 
central axis of the Man9-Trimer, largely in the V1/V2 region (Figure 18B), and distal from the central 
axis of the Mixed-Trimer (Figure 18D).  
The highest SASA change at sites where glycans were present, was at site 355 on Protomer 1, and sites 
185h and 411 on Protomer 3 of the Man9-Trimer; and sites 355 and 406 on Protomer 1, and 185e on 
Protomer 3 of the Mixed-Trimer. Site 355 was common to both trimers, and was occupied by a Man5 
glycan in the Mixed-Trimer.  
Only 6 of the 20 amino acids were featured in the top ten sites of SASA or AbASA change (Table 8); 
interestingly all of these were polar amino acids. Notably, of the ten sites with the highest ∆SASA and 
∆AbASA, six were located within PNGSs for the Man9-Trimer, and seven were located within PNGSs 
on the Mixed-Trimer (Table 8).   
Table 8: Amino acids featured in the top 10 sites of SASA and AbASA change 
  Man9-Trimer Mixed-Trimer 
Amino acid 
Combined 
total 
SASA AbASA SASA AbASA 
Asparagine 
(N-glycan 
position)* 
11 
1_355_m9, 
3_185h_m9, 
3_411_m9 
2_411_m9, 
3_185h_m9, 
3_462_m9 
1_355_m9, 
1_406_m9, 
3_185e_c 
1_185h_c, 
3_462_c 
Asparagine 
(X position)* 
2 3_186 - - 1_186 
Arginine 
(X position)* 
7 
2_185f, 
3_185f 
2_185f, 
3_185f 
3_185f 
2_185f, 
3_185f 
Arginine  
(non-PNGS)† 
5 2_617 1_511 
2_327, 
3_511 
3_511 
Threonine  
(T position)* 
6 - 1_408 
1_278, 
1_408, 
2_408 
1_408, 
2_408 
Threonine 
(non-PNGS) † 
1 - 1_511 - - 
Glutamine 4 1_185c 2_403 1_185c 2_403 
Glutamic 
Acid 
3 1_62 1_185a 1_64 - 
Lysine 1 2_171 - - - 
PNGS total 26 6 6 7 7 
* These amino acids are located within a PNGS, and their position refers to where they are found within the NXT/S motif. 
† The classification “non-PNGS” is used where an amino acid is found both within and outside of a PNGS, and is included 
in order to clearly distinguish the residues that are not located within a PNGS. 
Clare Garrard, GRRCLA001 
44 
Notably, although the third position of a PNGS can be occupied by either a threonine or a serine 
(NXT/S), no serine residues were included within the top sites of accessibility change, while seven 
threonine residues (six within PNGSs) were. This is particularly pronounced given that out of the 28 
PNGSs per protomer sequence, 12 are NXS sites, and 16 are NXT sites.  
In order to further investigate this, the PNGSs were grouped according to their motif (NXT or NXS), 
and the individual amino acid structures were further examined. At first glance, it would appear that 
threonine is found in the results more often because it is bigger than serine (93 Å3 as compared to 73 
Å3) (Darby and Creighton (1993), cited in Simpson, 2003). However, on further inspection, it becomes 
apparent that the threonine residues with a large change in accessibility recur at site 408 (Table 8), and 
that it is thus the position of the residue, and not the type, that is significant. This site, examined in its 
three-dimensional context, proves to be on an exposed edge of the trimer, distal from the gp120 
interfaces; interestingly, the size difference of the amino acids does appear to play a role here, since 
the threonine is adjacent to a serine on one side and a glycine on the other side – both relatively small 
residues – resulting in the threonine at this position being more exposed than the surrounding amino 
acids.  
 
3.6. Investigating Enzyme and Solvent Accessible Surface Area as a Proxy for Glycan Processing 
The secondary aim of this project was to investigate whether a computational approach to predicting 
the level of processing of a glycan can be used. Glycans are added to the nascent HIV-1 Env protein 
as Glc3Man9GlcNAc2 precursors, and the first glycan in the assembly line is the Man9 glycan, which 
is formed by the removal of three glucose residues from the precursor. The Man9 glycan is then 
processed by the barrel-shaped enzyme, ER α-mannosidase I, which removes one mannose residue to 
form Man8GlcNAc2. Thereafter, the glycan undergoes further trimming and processing (See Section 
1.4). 
3.6.1. Enzyme accessible surface area 
Recent work has highlighted the link between reduced glycan processing and lower solvent accessible 
surface area (Suga, Nagae and Yamaguchi, 2018); by the same token, the enzyme accessible surface 
area (EASA) was thought to have value in determining whether a Man9 glycan would be processed or 
not.  In order to investigate this, Naccess (Hubbard and Thornton, 1993) was used to calculate the 
absolute EASA for every glycan residue. Since ER Mannosidase I is a barrel-shaped enzyme (Xiang, 
Karaveg and Moremen, 2016) and fits around a Man9 glycan in order to process it (Figure 19A), one 
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side of the barrel was measured to determine the required probe radius for Naccess (Figure 19B) (See 
Section 2.6).   
Snapshots of the Man9-Trimer simulation were taken every 5 ns with CPPTRAJ (Roe and Cheatham, 
2013), and the EASA values were determined (using a probe with radius 13 Å) for the terminal (0MA) 
glycan residues (Figure 19C).  
The absolute EASA measurements of the terminal glycan residues were binned according to the 
processed form of the corresponding glycans in the Mixed-Trimer, and the distributions were plotted 
in order to establish whether there is a relationship between these two variables (Figure 20).  
The glycans that were allocated an unprocessed Man9 glycan form in the Mixed-Trimer had a higher 
EASA 52.3% more frequently than those that were given the intermediate Man5 glycan form. This 
was unexpected given that Man5 is more processed than Man9. Notably, the glycans that were 
processed to a Complex-glycan had higher EASA values 62.6% more frequently than the unprocessed 
Man9 glycans, and 64% more frequently than glycans that were intermediately processed to a Man5 
Figure 19: Basis of enzyme accessible surface area calculations for investigating processing prediction  
A: Barrel structured ER Man I (cage and PDB 1X9D structure) around a Man9 glycan (green ball structure) for trimming 
of a terminal mannose residue. B: The 13Å radius (red arrow) of the Naccess probe was determined by measuring ER 
Mannosidase from the centre to the edges (PDB 1X9D (Karaveg et al., 2005)). C: Man9 glycan showing its component 
residues. The terminal (0MA) residues (red arrows) were used in the accessible surface area calculations.  
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glycan. This indicates that while the EASA may not be able to distinguish between high mannose 
forms, it may be a useful method for distinguishing between high mannose and complex forms.  
 
The median of the EASA values was then calculated for every terminal (0MA) glycan residue of the 
Man9-Trimer, and these values were summed and averaged to give an aggregate EASA value for every 
Man9 glycan. This aggregate was then converted to a percentage and plotted onto the trimer to 
visualise the accessibility in structural context (Figure 21 A and C). By comparing the results to the 
processing levels on the Mixed-Trimer (Figure 21 B and D), it can be seen that this aggregate 
measurement predicts a similar degree of glycan processing as would be present on the Mixed-Trimer, 
and potentially on the HIV-1 Env trimer as a whole, since the Mixed-Trimer represents one form of a 
glycosylated Env trimer.  
Notably, both the intrinsic mannose patch around glycan 332, and the trimer-associated mannose patch 
at the protomer interfaces (See Section 1.4), are present on the EASA-predicted Man9-Trimer (Figure 
21).  
Figure 20: Investigating enzyme accessible surface area for processing prediction 
A: 13 Å MSMS surface of Man9-Trimer showing z-slice through the trimer The Envelope protein is represented in 
green. Cyan is used to show the slice through the MSMS surface rendering, revealing the protein shape underneath.  
B: Boxplots of enzyme accessible surface area were plotted using the EASAs of the terminal (0MA) residues of each 
glycan on the Man9-Trimer, taken every 5 ns and grouped according to their corresponding processed glycoform on 
the Mixed-Trimer. Points depict outliers. Differences between Man9 and Man5 glycans, and Man9 and Complex-
glycans were significant. 
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In contrast, while some of the complex glycans are correlated between the EASA-predicted Man9-
Trimer and the Mixed-Trimer, such as glycans 618 and 462, others are not comparably represented, 
such as the 185e glycans (Figure 21). 
Thus, since the glycan processing levels on the EASA-predicted Man9-Trimer and the Mixed-Trimer 
(used as a representative form of an HIV-1 Env trimer) were similar, it can be concluded that the EASA 
may provide a viable preliminary approach for determining the level of glycan processing present on 
the Env trimer. 
 
3.6.2. Solvent accessible surface area 
In addition to the EASA, the solvent accessible surface area (SASA) was investigated in the context 
of glycan processing. SASA is a more commonly used metric and has been linked to the level of glycan 
processing previously (Suga, Nagae and Yamaguchi, 2018), and was thus interesting to compare with 
the EASA values.  
Figure 21: Comparison of EASA prediction with Mixed-Trimer glycoforoms 
The EASA was explored as a proxy for predicting glycan processing. A and C: Man9-Trimer coloured by the average of 
the median EASA values for each glycan. For the “Increasing EASA” scale, a diverging green and purple colour scheme 
was used to indicate whether a glycan would be more likely to fall into the high mannose (green) or complex (purple) 
category, according to their EASA. B and D: The Mixed Trimer was included side-by-side with the plotted EASA values 
on the Man9-Trimer (A and C) in order to compare the results with what has been observed previously. 
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Similar to the EASA analysis, z-slices were taken through the Man9-Trimer (Figure 22A), and using 
a 1.4 Å probe, the SASA was calculated every 5 ns. Each SASA value was then assigned according to 
the processed glycoform on the Mixed-Trimer (Figure 22B) (See Section 2.6). 
The Man5 glycan SASA values were higher 54.5% more frequently than the Man9 SASA values, 
while the Complex-glycans had higher SASA values 56.4% more frequently than the Man9 glycans, 
and 51.7% more frequently than the Man5 glycans.  
 
 Figure 22: Investigating solvent accessible surface area as a proxy for glycan processing prediction 
A: 1.4 Å MSMS surface of Man9-Trimer showing z-slice through the trimer. The Envelope protein is represented in green. 
Cyan is used to show the slice through the MSMS surface rendering, revealing the protein shape underneath. B: Boxplots 
of solvent accessible surface area were plotted using Naccess scores from the terminal (0MA) residues of each glycan on 
the Man9-Trimer, taken every 5 ns and grouped according to their corresponding processed glycoform on the Mixed-
Trimer. Points depict outliers. The differences between the Man9 and Man5 distributions, and the Man9 and Complex-
glycan distributions were significant, despite a clear overlap of values.  
 
In order to compare the results from the SASA analysis to those of the EASA analysis, the medians 
were calculated for every 0MA residue and averaged. In order to create a finer gradient for the SASA 
values, since these were located within a narrower range than the EASA values were, the lowest of the 
average SASA values was subtracted from each average SASA value prior to their conversion to a 
percentile for plotting onto the trimer. The SASA-predicted trimer was compared both to the EASA-
predicted trimer and the Mixed-Trimer (Figure 23). 
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In contrast to the EASA-predicted Trimer, the level of processing that was predicted by the SASA 
values correlated to the processing on the Mixed-Trimer to a much lower extent. Notably, although 
the glycan at position 332 was indicated as a high mannose glycan, overall the intrinsic mannose patch 
and the trimer-associated mannose patch, which are conserved across strains (See Section 1.4), were 
not apparent on the SASA-predicted trimer (Figure 23).  It is possible that, because the SASA probe 
was a magnitude smaller and, therefore, a higher degree of accessibility occurred overall, this measure 
had a lower predictive power than that of the EASA.  
 
 
Figure 23: Comparison of processing levels of SASA-predicted Trimer, EASA-predicted Trimer, and 
Mixed-Trimer 
The SASA was compared to the EASA as a proxy for predicting glycan processing. A: EASA-predicted Trimer. B: SASA-
predicted Trimer. A diverging green and purple colour scheme was used to indicate whether a glycan would be more likely 
to fall into the high mannose (green) or complex (purple) category, according to their SASA or EASA. C: The Mixed-
Trimer was included in order to compare the predictions to a laboratory-derived processing, as well as to each other.  
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4. Discussion 
The picture alone, without the written word, leaves half the story untold ~ James Lafferty 
 
HIV-1 is a global pandemic, and the virus is able to evade the immune system as well as multiple 
treatments by its rapid evolution, aided by the presence of the glycan shield that is put in place by host 
machinery (Eigen and Schuster, 1977; Wei et al., 2003). These factors have contributed to a number 
of failed vaccine-strategy attempts (Klein et al., 2013), and while HIV-1 is no longer the life sentence 
it once was, there is still no efficacious vaccine, and there are numerous side effects associated with 
ARVs. Additionally, ARVs are not always available, especially in the developing world. Thus, many 
believe that the way forward is to design an effective HIV-1 vaccine (Atun et al., 2016; Stephenson 
and Barouch, 2016).  
We have come closer to this goal with the discovery of broadly neutralising antibodies (Walker et al., 
2009), and the realisation that even HIV-1 has characteristic patterns that feature on its glycan shield, 
forming targets for these antibodies (Doores et al., 2010; Pritchard, Vasiljevic, et al., 2015). While 
there have been multiple structural studies over the years, the difficulty of studying glycans 
experimentally, combined with a lack of knowledge of the importance of glycans, resulted in the 
glycan shield being largely overlooked initially (Kwong, 1999; Chang et al., 2007; Julien, Lee, et al., 
2013). With the knowledge that glycans form a part of most bNAb epitopes (Stewart-Jones et al., 
2016), there is a renewed push towards elucidating the structure and impact of the glycan shield in 
order to design an effective HIV-1 vaccine.  
This thesis adds to the body of work on the HIV-1 glycan shield. Molecular dynamics simulations (500 
ns in duration) were carried out on two HIV-1 Env trimer models that differed only in their glycan 
shields: a Man9-Trimer (including only Man9 glycans) and a Mixed-Trimer (including Man9, Man5, 
and Complex-glycans). The glycan distribution of the Mixed-Trimer was defined using three recent 
publications, which outlined mass spectrometry work on determining the glycan profiles of HIV-1 Env 
clones (Behrens et al., 2016; Panico et al., 2016; Cao et al., 2017), in order to generate a biologically 
relevant model that resembled an HIV-1 Env trimer described in the laboratory (Figure 5C).  
Overall, the results (Chapter 3) indicated that differences are indeed present due to the distinct 
glycoforms on these two trimers, and model-specific changes in accessible surface area of Man9 
glycans, that are later processed, point to a rudimentary processing prediction method. This chapter, 
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therefore, moves on to discuss these findings in detail, outlining the results in light of the aims of this 
project, and setting the work against a backdrop of the body of literature. 
 
4.1. The Influence of Different Glycoforms 
The primary aim of this project was to investigate how different types of glycans influence interactions 
with the protein and surrounding glycans by comparing two computationally generated trimer models 
where one model was uniformly glycosylated with Man9 glycans and the other with a mix of glycans 
(Man9, Man5 or Complex-glycans; see Section 2.2). In this section, the impact of the different 
glycoforms on glycan occupancy, RMSD, RMSF, hydrogen bonding, and solvent and antibody 
accessible surface area will be discussed.  
4.1.1. Glycoforms influence the level of glycan occupancy due to spatial constraints 
It is well-known that spatial constraints hinder glycan processing in physiological conditions (Doores 
et al., 2010; Pritchard, Vasiljevic, et al., 2015). In this study, spatial considerations introduced by 
different glycoforms, i.e. the size and branching of different glycans, were also seen to affect glycan 
occupancy for computational glycosylation. Since glycans are added and processed as the protein is 
being made (Moremen, Tiemeyer and Nairn, 2012), and glycan occupancy has been seen to differ in 
mass spectrometry experiments both on trimers (Cao et al., 2017, 2018) and gp120 monomers (Yu et 
al., 2018), this may have relevance for biological conditions, as well as computational glycosylation 
algorithms.  
Differences in glycan occupation between the ten Man9-Trimers and the Mixed-Trimers occurred at 
two sites. Site 185h, which is situated on the V2 loop, had a noticeably lower occupancy on the Mixed-
Trimers; and site 392, which is situated on the V4 loop, had a considerably lower occupancy on the 
Man9-Trimers (Figure 6A and B). The V1/V2 and V4 loops are both densely glycosylated regions of 
HIV-1 Env (Figure 5); thus it is unsurprising that there appear to be spatial constraints for the glycans 
in these regions.  
Site 185h, which had lower occupancy on the Mixed-trimers (Figure 6A), is located at the apex of the 
trimer (Figure 6B) and surrounded by glycans from the V1/V2 region, amounting to a dense cluster of 
nine Complex-glycans on the trimer apex. Although incomplete on the Mixed-trimers, the 
computational glycosylation process successfully glycosylated each of these sites on the Man9-
Trimers. One explanation for this may be due to the structures of the glycans themselves; the Complex-
glycan used in this study has an extra sugar residue (See Section 2.2), which contributes to a longer 
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glycan structure compared to a Man9 glycan, thereby limiting the size of the Complex-glycan rich 
cluster.  
Cao et al. (2017) also found reduced glycan occupancy at site 185h, as well as 185e of the 
BG505.SOSIP trimer, with 89% and 82% occupancy respectively. Although the results from Yu et al. 
(2018) are based on a gp120 monomer, they include 99 strains of HIV-1, and these results clearly 
illustrate the differing occupancy of PNGSs on Env. Site 185h was not included in the study by Yu et 
al. (2018), but nearby sites on the V1/V2 loop exhibit incomplete glycosylation, averaging 70% 
occupancy.  
In contrast to site 185h at the apex, site 392 is located towards the outside of the lobes of gp120, near 
the CD4 binding site (Figure 6B), and had a considerably lower occupancy on the Man9-Trimers 
(Figure 6A). Interestingly, the glycan at site 392 takes on a Man9 glycoform in both trimers. However, 
other glycans that cluster nearby on the folded protein are different glycoforms on the two trimers, and 
it is likely that this causes the spatial constraint that results in occupancy differences. On the Man9-
Trimers, glycans 197 and 276, which also cluster around the CD4 binding site, are Man9 glycans. 
However, on the Mixed-Trimers, these are Man5 glycans and thus are shorter and take up less space 
(Figure 5) – leaving more room for the addition of glycan 392 in this region.  
Although variable occupancy was not observed in the experiments by Cao et al. (2017, 2018), the 
average occupancy across strains for site 392 in the experiment by Yu et al. (2018) was 84%, 
highlighting the variable occupancy of this site.  
Interestingly, sites 618 and 625 had greatly reduced occupancy (63.8% and 62% respectively) in the 
study by Cao et al. (2017), which was not reflected in the computationally glycosylated models. This 
may be due to the presence of a membrane when glycosylation takes place in vivo (Checkley, Luttge 
and Freed, 2011), as opposed to the computational models that do not contain a membrane, and thus 
have more space available for the addition of glycans at these sites. Thus, future experiments should 
perhaps take into account the steric hindrance that is present at membrane-proximal sites. 
Thus, we can see that the presence of different glycoforms does indeed impact the glycan occupancy 
at various sites – and importantly, not just sites that are located in close proximity on the linear 
sequence, but also sites that are located close together in three-dimensional space, since a larger glycan 
can be accommodated if there is a small glycan on a nearby site.  
The final Man9-Trimer did not include a glycan at site 363 on Protomers 1 and 2, and at site 392 on 
Protomers 2 and 3; while the final Mixed-Trimer lacked glycans at sites 386 and 462 on Protomer 1, 
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185h and 392 on Protomer 2, and 363 on Protomer 3 (Table 3). Notably, each of these sites exhibited 
variable occupancy across HIV-1 Envelopes in the study by Yu et al. (2018), highlighting that 
incomplete glycosylation occurs in nature, and supporting the validity of these models as possible 
forms of Env.  
4.1.2. The Mixed-Trimer is more stable than the Man9-Trimer 
As well as affecting the glycan occupancy, different glycoforms also impacted the stability of the 
trimers. The RMSD and RMSF data highlight the greater stability of the Mixed-Trimer, which 
generally achieved lower deviations and fluctuations from the reference structure than those of the 
Man9-Trimer (Figure 7 and Figure 8).  
The higher levels of hydrogen bonding on the Mixed-Trimer (1 332 406, compared with 1 067 251 for 
the Man9-Trimer) may contribute to this difference in stability. The only difference between the two 
trimers was their glycan shields and, therefore, the impact of different glycoforms on hydrogen 
bonding was examined, since this has been shown to be important to the integrity of the glycan shield 
(Stewart-Jones et al., 2016).  
Interestingly, Man5 and Man9 glycans at equivalent positions between the two trimers contributed to 
the longevity of hydrogen bonding to a similar degree; however, the difference between equivalent 
Complex-glycans and Man9 glycans was significant, and Complex-glycans had a 29.7% higher 
median presence in the hydrogen bonds over time. (Table 7). 
The lack of significant differences between the hydrogen bonding involvement of equivalently 
positioned Man5 and Man9 glycans may be due to the similarity in branching structure of the Man5 
and Man9 glycans (See Section 2.2), as well as their location in glycan dense regions. In contrast, the 
Complex-glycans could extend beyond the rest of the glycan shield due to their greater length. 
Additionally, the Complex-glycans were frequently located in glycan-sparse regions, allowing for 
interaction with glycans located further away due to the unrestricted movement from their attachment 
point, rather than having to navigate a densely glycosylated space. 
Interestingly, another study (Gift et al., 2017) identifies complex glycans as reducing stability by 
comparing the thermal stability of viral Envs produced in wild-type HEK-293T cells to that of those 
produced in the presence of kifunensine (which would result in uniformly Man9 glycan shields, such 
as with the Man9-Trimer). This is in contrast to what was observed here, where the more biologically 
relevant Mixed-Trimer, which includes complex glycans, is more stable than the Man9-Trimer. 
Notably, while molecular dynamics has been used to explore factors that may influence thermal 
stability (Gu et al., 2018), the direct relationship between thermal stability and the RMSD (used as a 
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measure of stability in MD) of a molecule during a simulation has not been investigated. While more 
work may be necessary to understand these differences, it is clear that trimer stability is important for 
the elicitation of neutralising antibodies (Feng et al., 2016).  
4.1.3. The presence of complex glycans at the HIV-1 Env apex may be important for interprotomer 
stabilisation 
A large proportion of Complex-glycans were present on the apex of the Mixed-Trimer on the V1/V2 
loop, and notably this is where the majority of its 177 778 interprotomer stabilising hydrogen bonds 
occurred (Figure 10B and D). Laboratory studies have shown that trimers which have been chemically 
cross-linked between their gp120 monomers at the trimer apex, using glutaraldehyde, have increased 
stability and antigenicity (Schiffner et al., 2018), and it is plausible that the interprotomer hydrogen 
bonds between Complex-glycans at the trimer apex in this study fill the same role. 
In contrast, although both trimers exhibited their highest levels of hydrogen bonding at the trimer apex, 
the 96 551 Man9-Trimer interprotomer hydrogen bonds occurred largely around the sides of the trimer, 
with only one notable apex-located interprotomer interaction (25 757 hydrogen bonds) between 
glycans 185h on Protomer 1 and glycan 160 on Protomer 3 (Figure 9B).  
The highly conserved glycan at site 197 (Travers, 2012), which is important to neutralisation resistance 
in multiple HIV-1 strains (Wyatt et al., 1995; Ly and Stamatatos, 2000; Li et al., 2008; Utachee et al., 
2010; O’Rourke et al., 2012), was involved in the other 67.5% of the dominant interprotomer 
interactions on the Man9-Trimer.  
Complex-glycans were present in 83.5% of the dominant interprotomer hydrogen bonds on the Mixed-
Trimer. The equivalently positioned glycans on the Man9-Trimer were only involved in 32.5% of the 
dominant interprotomer hydrogen bonds. As before, this may be due to the extension of the Complex-
glycans beyond the rest of the glycan shield, as well as their added length compared to the Man9 
glycans, allowing the Complex-glycans to form long-distance interactions with glycans on other 
protomers, and contributing to increased stability of the Mixed-Trimer compared to the Man9-Trimer.  
The interprotomer interactions on the HIV-1 Env trimer have not been closely investigated, although 
they are referred to in passing (for example, in Stewart-Jones et al. (2016)); and some interactions, 
such as between the V1/V2 stem and the tip of the neighbouring protomer V3 loop, similar to the 
glycan 197 interactions on the Man9-Trimer, have been described (Li et al., 2008). Thus, this is an 
area that could benefit from further research, especially given the evidence that complex glycans at the 
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apex may contribute to trimer stability and antigenicity, which are important for the design of vaccine 
immunogens. 
4.1.4. Scissoring and trimer asymmetry in Man9-Trimer likely caused by lack of stabilising complex 
glycans 
Interestingly, Protomers 1 and 3, as well as Protomers 2 and 3, interact, but there is no notable 
interprotomer interaction present between Protomers 1 and 2 of the Man9-Trimer. This may contribute 
to the scissoring of protomers that was observed in the simulation of the Man9-Trimer, and which 
resulted in an exposed CD4 binding site between Protomers 1 and 2 (Figure 12).  
This is similar to the results described in the study by Lemmin et al. (2017), where MD simulations 
were carried out using a uniform Man5 glycan shield on the clade A BG505 SOSIP.664 trimer. In both 
the current study, and the study by Lemmin et al. (2017), one of the three CD4 binding sites was 
exposed, while access to the other two was restricted. Interestingly, scissoring was not observed in the 
study by Ferreira et al. (2018), which used a uniformly glycosylated Man9 shield, similar to the Man9-
Trimer here. However, Ferreira et al. (2018) used a clade C strain (CAP45.G3) of HIV-1, rather than 
the clade A BG505 SOSIP.664 trimer that was used in this study, and it is possible that differences in 
the distribution of PNGSs between the sequences may have contributed to the contrasting observations. 
The Mixed-Trimer, unlike the Man9-Trimer, did not exhibit asymmetry in its interprotomer hydrogen 
bonding, and limited scissoring was observed (See Section 3.4.3). The strong 3-way interprotomer 
stabilisation on the Mixed-Trimer may prevent the occurrence of scissoring.  
Consequently, it would appear that complex glycans, including the Complex-glycans used to 
glycosylate the Mixed-Trimer in this study, and which the Man9-Trimer lacks, are important to 
forming the stabilising hydrogen bonds between the protomers on the trimer apex. However, a different 
underlying protein structure, where the location of PNGSs and Man9 glycans allow interprotomer 
interactions, may contribute to the lack of scissoring observed for other Man9-glycosylated trimer 
models such as in the study by Ferreira et al. (2018).  
These differences are important to note if computational methods are to be used in antibody studies. 
For example, the prediction of the degree of interaction between the CD4 binding site antibody, 
VRC01 (Wu et al., 2010), is likely to be different for the Man9-Trimer, which exhibited scissoring, as 
compared to the Mixed-Trimer, which did not.  
It is worth noting that the study by Lemmin et al. (2017) reported the observation of scissoring in the 
0.5 – 1.0 μs range of the simulation. Since one of the caveats of molecular dynamics relates to the 
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length of the simulation, where all conformations are known to have been sampled, it could be 
speculated that perhaps the Mixed-Trimer would exhibit scissoring if the 500ns simulation used here 
had been continued for a longer time span, or if a replica exchange method (which samples more states) 
had been used, such as in the study by Yang et al. (2017). However, it could also be argued that the 
study by Lemmin et al. (2017) did not include complex glycans, which may have negated the scissoring 
effect.  
4.1.5. The 185e glycan compensated for an absent 185h glycan, highlighting the importance of 
interactions at the trimer apex 
The importance of the Complex-glycans to interprotomer interactions is highlighted by the Complex 
185e glycan filling the role of the absent 185h Complex-glycan on Protomer 2 of the Mixed-Trimer. 
On Protomers 1 and 3, glycan 185e played a negligible role in interprotomer hydrogen bonding 
interactions while glycan 185h featured in the dominant interprotomer interactions. However, on 
Protomer 2, which lacks the 185h glycan, glycan 185e was involved in the dominant interprotomer 
interactions (Figure 11 and Table 5). This points to structural rearrangements within the glycan shield, 
such as those observed in Ferreira et al. (2018), taking place to maintain the integrity of the glycan 
shield, and the inclusion of interprotomer interactions in this rearrangement is remarkable.  
4.1.6. Hydrogen bonding is more dispersed on the Mixed-Trimer than on the Man9-Trimer 
In addition to the stabilisation caused by the situation of Complex-glycans at the trimer apex, the 
greater dispersion of glycan-glycan hydrogen bonds over the Mixed-Trimer as compared to the Man9-
Trimer may also increase its stability.  
The Mixed-Trimer had 8% more unique glycan pairs that formed hydrogen bonds compared to the 
Man9-Trimer. While some asymmetry was seen in the favouring of Protomer 1 glycans in its hydrogen 
bonding (Figure 9B), overall the Mixed-Trimer’s hydrogen bonds were more dispersed over the 
surface of the trimer than was seen on the Man9-Trimer. Additionally, the Mixed-Trimer had 13 
glycans that were predominantly present in its set of glycans involved in hydrogen bonding, compared 
to 7 on the Man9-Trimer. The larger group of predominantly present glycans observed for the Mixed-
Trimer may have contributed to the better compensation on the Mixed-Trimer when one glycan is 
removed, such as with glycans 185e and 185h (Section 4.1.5), where the hydrogen bonds were 
redistributed.  
Additionally, the greater dispersion of hydrogen bonds on the Mixed-Trimer may suggest a less easily 
penetrated glycan shield: Stewart-Jones et al. (2016) point out the importance of glycan-glycan 
interactions, and notably hydrogen bonds, to maintaining the integrity of the glycan shield. When the 
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glycan shield acts as a barrier to antibodies (Wei et al., 2003), greater dispersal of hydrogen bonds 
may help to prevent penetration of the glycan shield by these antibodies at areas of weaker bonding. 
On the other hand, when glycans form part of an antibody’s epitope (Gray et al., 2011; Walker et al., 
2011), more closely bonded glycans over the glycan shield may impede the binding of these antibodies.  
Although differences in the dispersion of hydrogen bonds were observed between the trimers, one 
commonality was that the hydrogen bonds were unevenly distributed across protomers (Figure 9 A 
and B). While more sampling may have resulted in evenly dispersed hydrogen bonding, the uneven 
spread of hydrogen bonding may be valid in a biological context if the asymmetry occurs during the 
time at which an antibody is binding. Notably, some antibodies, such as PG9, interact asymmetrically 
with HIV-1 Env (Julien, Lee, et al., 2013), and thus the asymmetry in hydrogen bonding could be 
beneficial in such cases.  
While much focus was placed on the hydrogen bonding dynamics of the two trimers in this study, as 
these have been shown to be important to the glycan shield (Stewart-Jones et al., 2016), this does not 
rule out the occurrence of other interactions, such as Van der Waals, and hydrophilic interactions, 
which could be addressed in future studies.  
4.1.7. Areas around glycans, including important epitopes, exhibit the largest change in accessibility, 
regardless of glycoform 
While glycoforms were important to the dynamics of the HIV-1 Env trimers in this study, it was not 
the type of glycan as much as their presence or absence that most affected the accessible surface area 
of protein residues. This was shown by the SASA and AbASA analysis, where the change in 
accessibility on removal of glycans was determined for the Man9-Trimer and Mixed-Trimer at every 
protein residue (See Section 3.5).   
Interestingly, the residues included in the top ten sites of change in accessibility (upon glycan removal), 
predominantly occurred in the V1/V2 and V4 loops (Figure 16A and B). This may be due to the 
exposure of these regions compared to other regions of HIV-1 Env, as well as the high density of 
PNGSs (contributing to a high level of shielding when glycans are present).  
Strikingly, out of the 20 amino acids, only 6 were featured in the top ten sites of median SASA or 
AbASA change (Table 8), and all were polar amino acids. This may be explained by a preferential 
interaction of glycans, which are highly polar by nature, with polar amino acids; this interaction would 
reduce accessibility of these sites in the presence of glycans.  
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Additionally, of the top sites of median SASA or AbASA, 60% were within a PNGS on the Man9-
Trimer, and 70% were within a PNGS on the Mixed-Trimer (Table 8), highlighting the role of glycan 
proximity in determining the accessibility of a protein residue.  
This is important in the context of antibody binding, since the sites that are more accessible in the 
absence of a glycan, such as sites 411, 462 and 185h as highlighted as in the antibody accessible surface 
area analysis (Table 8), may have important roles in exposing antibody epitopes. For example, the 
removal of glycan 185h would create a glycan hole at the apex of the trimer, which may aid the 
PGT145 antibody (Walker et al., 2011) in extending into the junction of the three protomers to contact 
the underlying protein epitope (Liu et al., 2017). Similarly, gp120 sites 455 - 465 are important for 
VRC01 binding (Zhou et al., 2010), and thus the removal of the glycan at site 462 may improve the 
binding of VRC01 by exposing this region.  
4.1.8. Repeated sites of high accessibility change may offer targets for creating glycan holes 
Notably, a number of the sites with high levels of change in accessibility due to the presence of a 
glycan were repeated between the two trimers (Table 8). If this observation is consistent across a wide 
variety of models, then these sites may be useful targets for creating glycan “holes” in the interest of 
designing immunogens for the priming step of a prime-and-boost vaccine strategy.  
Glycan holes have been explored in a number of studies – from observing those that occur naturally 
when a glycan is absent, such as the hole created by a missing 197 glycan on a JR-FL trimer (Crooks 
et al., 2015), or those generated by the absence of glycans at sites 241 and 289 on a BG505 SOSIP.664 
trimer (McCoy et al., 2016); to those created in the laboratory, as was carried out by Zhou et al. (2017).  
In this latter study (Zhou et al., 2017), four glycans were removed (by mutating their PNGS motifs) 
around the CD4 binding site of clade C Envelopes: glycans 197, 276, 363, and a glycan from the 460-
463 region (notably, glycan 462 was found to be a site of high change in accessibility in the current 
study (Table 8)). Deglycosylation resulted in 10 to 100-fold increase in sensitivity to neutralisation at 
the CD4 binding site (Zhou et al., 2017). Although not carried out in the study, it was proposed that 
the deglycosylated trimers could act as primers, and by restoring the removed glycans prior to the 
boosting step, antibodies may develop glycan tolerance either through direct engagement (Garces et 
al., 2015) or by accommodating shifts in the glycan conformation (Stewart-Jones et al., 2016), as has 
been observed in B-cell ontogeny studies.   
Furthermore, glycan holes have been studied in the context of how complete (i.e. with a higher number 
of glycans, and fewer glycan holes) a glycan shield is at viral transmission (Wagh et al., 2018), 
highlighting that more complete glycan shields are advantageous to the development of broadly 
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neutralising antibodies, and suggesting that the exclusion of glycan holes is important to the 
development of neutralisation breadth.  
Thus, these repeated sites that impact the accessibility of the Env trimer may be worth exploring further 
in the context of developing bNAbs.  
4.1.9. Further glycan heterogeneity may affect the dynamics of the glycan shield 
It is apparent that, while the heterogeneity of the glycan shield of the Mixed-Trimer is a better 
representation of the HIV-1 Env than has previously been used in MS studies, it is still not fully 
representative of the diversity that occurs within circulating viral strains.  
Tri- and tetra-antennary glycans are known to be found on the glycan shield (Crispin, Ward and 
Wilson, 2018); these glycans are larger than any of the glycans represented in this study (which used 
a bi-antennary Complex-glycan), and thus may affect the dynamics of the glycan shield in a different 
way.  
The fucosylation of the glycan core has not been explored either, and whether this affects the dynamics 
of the glycan shield as a whole, or just the dynamics of the individual fucosylated glycans, is as yet 
unknown and may be important for those antibodies that contact the Man3GlcNAc2 core.  
Additionally, while molecular dynamics is a good method for exploring glycan rotamers (Woods and 
Tessier, 2010), the 500 ns length of the simulation may not have been enough to fully sample all 
possible rotamers at every glycan position. While the scope of the current project did not allow for 
longer simulations to be generated prior to analysis, the conformational sampling could be improved 
by increasing the length of the study, or using replica exchange.  
Finally, even within the set of glycans that was used, different linkages are possible for both the Man5 
glycan and the Complex-glycan, and it remains to be seen to what extent these linkages affect the 
dynamics of the glycan shield.  
4.1.10. Non-identical glycosylated PNGSs may influence the dynamics 
It was noted previously that different glycoforms changed the levels of glycan occupancy, and also 
that differing glycan occupancy is to be expected across even clonal HIV-1 Env populations (See 
Section 4.1.14.1.14.1.14.1.1). While this underscores the applicability of the results, it still leaves the 
question of what differences might be observed were identical PNGSs glycosylated on both trimers.  
The most notable implication is that two Complex-glycans were not added to the Mixed-Trimer at 
positions where Man9 glycans were added to the Man9-Trimer (positions 462 on Protomer 1, and 185h 
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on Protomer 2). This is a particularly interesting omission, since it reduces the number of Complex-
glycans present on the Mixed-Trimer, and yet the Mixed-Trimer still has a higher level of hydrogen 
bonding and stability compared to the Man9-Trimer, highlighting the importance of Complex-glycans 
in these functions. Additionally, these PNGSs were among the highest sites of change in antibody 
accessibility when a glycan was removed (See Section 3.5). 
The omission of the glycan at position 363 on Protomer 2 of the Man9-Trimer may have had some 
influence on the dynamics, but as this glycan (when present) did not form the predominantly present 
or absent hydrogen bonds, and it was not present in the set of PNGSs of largest change in solvent or 
antibody accessible surface area, the effects of its omission would likely have had a fairly low impact 
on the general dynamics of the Man9-Trimer. 
The other omitted glycans on the two trimers map largely equivalently: both trimers lack the Man9 
glycans at position 392 on Protomer 2, and 363 on Protomer 3; while the last missing Man9 glycan is 
6 amino acids apart on Protomer 1 of the two trimers, at position 392 on the Man9-Trimer, and position 
386 on the Mixed-Trimer. It is unlikely that these largely equivalent missing glycans would have 
resulted in significantly different dynamics between the two trimers, however, future MD studies will 
add further evidence to this assumption.     
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4.2. Potential for Glycan Processing 
The secondary aim of this project was to estimate the potential for glycans to be further processed from 
the initial Man9 glycan. Here, as a preliminary investigation, this was done by carrying out enzyme 
and solvent accessibility analyses, since the physical space available to glycan-processing enzymes 
may influence the subsequent processing.  
Since the intrinsic mannose patch and the trimer associated mannose patch occur in areas where there 
are spatial constraints for processing enzymes (Doores et al., 2010; Pritchard, Vasiljevic, et al., 2015) 
(See Section 1.4), areas of high accessibility were expected to correspond to more processed glycans 
(tending towards complex), and areas of low accessibility were expected to correspond to high 
mannose glycans, which are less processed. 
4.2.1. The choice of ER ManI as opposed to other enzymes 
The ER α-mannosidase I enzyme was used as the basis for the enzyme accessibility calculations, since 
this enzyme targets Man9 glycans, and the Man9-Trimer was used as the input for the Naccess 
(Hubbard and Thornton, 1993) calculations. Although the Golgi mannosidase I A – C enzymes also 
process high mannose glycans once Env has moved to the Golgi apparatus following oligomerisation 
(Doores et al., 2010), these enzymes were not included in the preliminary investigation.  
In the study by Lobsanov et al. (2002), it was shown that the ER and Golgi α-mannosidase I enzymes 
were structurally similar. On overlaying the Penicillum citrinum α-mannosidase I enzyme (which is in 
the same class as Golgi α-mannosidase I; PDB ID: 1KKT (Lobsanov et al., 2002)) with the 1X9D  
structure (Karaveg et al., 2005) used to determine the probe size for ER Man I, it was found that these 
enzymes would require the same probe size (data not shown) to measure the enzyme accessible surface 
area, and thus the use of only the ER α-mannosidase I enzyme in this preliminary study, was justified.  
4.2.2. The impact of oligomerisation 
Since trimming of Man9 glycans (from Man9 to Man8GlcNAc2) takes place while Env is in protomeric 
form in the ER, and then the majority of trimming takes place following trimerisation and translocation 
to the Golgi, the accessibility calculations were carried out on a trimer. However, it may be interesting 
to compare this to calculations performed on a protomer in a future study in order to understand how 
oligomerisation may affect processing prediction.  
4.2.3. EASA may be useful for differentiating high mannose and complex glycans 
With Complex-glycans exhibiting higher EASA measures 62.6% and 64% more frequently in 
comparison to Man9 and Man5 glycans respectively, the EASA calculations provide a rudimentary 
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method for predicting whether a glycan will be of a complex or high mannose form. The EASA 
distribution differences were significant, with p-values in the region of 1 x 10 -100 when comparing 
Complex-glycans to either high mannose distribution.  
The impact of this was clear when an aggregate measure of the accessibility of the terminal glycan 
sites was plotted onto the trimer and compared to the Mixed-Trimer: the intrinsic mannose patch 
(Doores et al., 2010) and trimer associated mannose patch (Pritchard, Vasiljevic, et al., 2015) (See 
Section 1.4) were readily identifiable according from the processing prediction results (Figure 21). 
Since snapshots were taken every 5 ns, giving a total of 90 snapshots, these results should reflect a 
representative sample of the accessibility. 
4.2.4. Higher predictive power of the EASA compared to the SASA  
Since the a higher solvent accessible surface area has previously been linked to increased glycan 
processing (Suga, Nagae and Yamaguchi, 2018), this was also measured for the terminal residues of 
every glycan. Interestingly, when normalised and compared to the EASA-predicted Man9-Trimer and 
the Mixed-Trimer in structural context, it became apparent that the SASA overrepresented the level of 
processing that would occur on the trimer (Figure 23). Thus, it appears that the EASA may provide a 
more accurate prediction of the glycan processing that might occur in vivo compared to the commonly 
used SASA measure.  
4.2.5. EASA indicates potential for a higher number of complex glycans in the Mixed-Trimer 
Unexpectedly, the Man9 glycans had a higher EASA than the Man5 glycans 52.3% more frequently; 
this was significant with a p-value of 2.04 x 10-5. Here, however, it could be argued that in fact some 
of the Man9 glycans should have been allocated a complex glycoform, since Man9 was allocated as 
the default when glycan processing information was lacking or contradictory (See Section 2.2). This 
was also reflected in the structural plot of the EASA values, which showed potential for greater 
processing at a number of sites when compared with the Mixed-Trimer (Figure 21). 
Indeed, in the findings of Cao et al. (2018), virion derived BG505 Env glycan shields had a higher 
proportion of complex glycans than was found for the recombinant BG505 SOSIP.664 constructs; this 
indicates that the Mixed-Trimer (which is based on BG505 SOSIP.664) may be able to accommodate 
more complex glycans than was assigned in this study. 
4.2.6. Glycoforms chosen at variable and uncharacterised sites align well with EASA predictions 
In cases where the information on the glycoform at any given site was variable, inadequate, or 
conflicting, the glycoform was assigned to represent the available information as closely as possible, 
or a Man9 glycan was added as the default (See Section 2.2).  
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Sites 197, 276 and 355 were assigned a Man5 glycan due to their intermediate levels of processing. 
Interestingly this is reflected on the EASA-predicted trimer: the 197 glycans are all slightly processed 
high mannose glycans, the 355 glycans fall into an intermediate category of processing and may form 
hybrid glycans, and the 276 glycans each take on a different category, with one high mannose, one 
intermediate-complex, and one complex (Figure 21). Site 406 was assigned a Man9 glycan based on 
incomplete and conflicting information for this site; all of the glycans at position 406 were predicted 
to be a slightly processed high mannose on the EASA-predicted trimer (Figure 21).  
4.2.7. The effect of rotamers on accessibility may not be sufficiently represented 
Since the simulations are unlikely to have sampled all possible conformations, it is likely that not all 
glycan rotamers were taken into account, which may have affected the processing results. However, 
since it is likely that not all conformations are sampled while glycans are being processed in vivo, these 
results represent one possible form of processing that could occur.  
4.2.8. Processing prediction and glycan holes 
The ability to predict the level of processing may be useful when designing glycan holes for vaccine 
immunogens, since the glycoforms may affect interactions with antibodies. For example, Behrens et 
al. (2018) noted only slight increases in the glycan processing of glycan 363, in spite of the deletion 
of the glycans at the neighbouring sites (197, 386, and 462). In contrast, Zhou et al. (2017) noted a 
change in processing from high mannose to complex glycans at positions surrounding the hole created 
by the removal of glycans 197, 276, 363, and a glycan from the 460-463 region. Therefore, the 
computational prediction of glycan processing would be useful to aid laboratory investigations, and 
this preliminary investigation shows promise as one method to do so.  
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5. Conclusion 
We shall not cease from exploration, and the end of all our exploring will be to arrive where we 
started and know the place for the first time ~ T S Eliot 
 
This computational study set out to examine the influences of different glycoforms, specifically Man9, 
Man5 and Complex-glycans, on the accessibility and stability of the HIV-1 Env glycan shield, and, 
further, to offer a method of predicting the type of glycoform by estimating the degree of glycan-
processing based on glycan location and accessibility.   
One significant finding to emerge from this study is that complex glycans appear to play an important 
role in stabilising the Env trimer. This is notable, because trimer stability is important for eliciting 
neutralising antibodies. Furthermore, the Complex-glycans in this study formed substantial 
interprotomer hydrogen bonding interactions at the trimer apex, which appear to contribute to 
preventing the scissoring phenomenon that was observed on the Man9-Trimer, which, comparatively, 
did not have substantial apex interprotomer interactions. This may be an important consideration for 
vaccine and immunogen design if computational methods are used since dynamical differences were 
observed here and, thus, a more representative trimer (such as the Mixed-Trimer) may be more suited 
to this task.   
Interestingly, the Complex-glycans had a much greater impact on the dynamics of the glycan shield, 
compared to the Man9 glycans, than the Man5 glycans did; in fact, the Man5 and Man9 glycans 
showed no significant differences in their hydrogen bonding involvement across frames.  An 
implication of this is that previous MD studies using uniformly high mannose glycan forms are likely 
to agree in terms of their hydrogen bonding dynamics. However, the immense impact of the Complex-
glycans on the dynamics of the glycan shield highlights a weakness in these prior studies. It may be 
useful to repeat some of these studies using a glycan shield comprising a representative mix of glycans. 
Notwithstanding the relative simplicity of the Mixed-Trimer model in this study, this model gives a 
better insight into the dynamics of a more natively glycosylated trimer than any previous model.  
Given the impact of the bi-antennary Complex-glycans used in this study, the question of how hybrid 
glycans, and tri- and tetra-antennary complex glycans might affect the glycan shield dynamics arises. 
A natural progression of this work would be to further diversify the broad classifications of glycans 
used to define the Mixed-Trimer. Further, it may be interesting to compare the Env glycan shields 
from different cell types, which would vary in their complex glycan forms (Pritchard, Harvey, et al., 
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2015), in order to understand whether some cells may allow better neutralisation of HIV-1. 
Additionally, comparing the dynamics of different strains, or recombinant with virion-derived trimers 
as in Cao et al. (2018), as well as isolates from early and late infection, would be useful in expanding 
our knowledge of how the dynamics of the HIV-1 Env glycan shield varies.  
This study also found that the EASA may be useful as a rudimentary tool for predicting whether a 
glycan would be high mannose or complex; additionally, the EASA appears to be more effective than 
the SASA as a proxy for predicting the level of glycan processing. This finding may prove useful in 
future studies, since a computational tool for prediction is much less costly and time-consuming than 
a mass spectrometry experiment.  
Although a relatively simple mixed-glycan model was used, and the length of a molecular dynamics 
study can always be extended, this thesis has provided a deeper insight into the HIV-1 Env glycan 
shield, offering a new perspective of its dynamics. By comparing a uniformly glycosylated trimer with 
a more representative heterogeneously glycosylated trimer, it became apparent that a more 
representative glycan shield has different dynamics to a uniform glycan shield. Additionally, the role 
of physical accessibility in glycan processing was highlighted, and a preliminary method based on the 
enzyme accessibility was explored as a glycan-processing prediction method. These results provide a 
useful foundation for future structural and molecular dynamics work to build upon. Overall, an 
increased understanding of the dynamics of the HIV-1 Env trimer, in relation to its adaptations, 
mutations, and neutralisation by antibodies, will be helpful for designing immunogens that may 
eventually lead to an HIV-1 vaccine. 
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Appendix  
 
 
Supplementary Figure 1: HXB2 aligned 4TVP template with PNGSs highlighted 
The 4TVP template sequence was aligned to the HXB2 sequence (downloaded from 
https://www.hiv.lanl.gov/content/index) in SeaView (Gouy, Guindon and Gascuel, 2010). Annotations were added to show 
HIV-1 regions, and numbers of PNGSs. Although shown as X in the alignment, since they are modified from the standard 
amino acid code by the software when a glycan is added, PNGSs take on the form NXT/S (where X is any amino acid 
except for proline). Blue and pink lines on the left indicate the gp120 (blue) and gp41 (pink) subparts.  
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Supplementary Figure 2: Heatmap showing glycan-glycan hydrogen bonding on Man9-Trimer 
The number of hydrogen bonds between glycans on the Man9-Trimer were plotted onto a heatmap in order to investigate the 
distribution of hydrogen bonds across individual glycans, with a grid used to represent protomer divisions. Main upward-right 
diagonal shows intra-protomer interactions whereas the remaining blocks depict interprotomer interactions. The interactions 
between glycans 295 and 332 of protomer 1, shown in yellow, contribute the highest number of hydrogen bonds between any 
two glycans on the Man9-Trimer. Note: glycans 392 of Protomer 1, 363 and 392 of Protomer 2, and 363 of Protomer 3 were 
not added to this trimer (See Table 3), and thus are not shown on the heatmap. 
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Supplementary Figure 3: Heatmap showing glycan-glycan hydrogen bonding on Mixed-Trimer 
The number of hydrogen bonds between glycans on the Mixed-Trimer were plotted onto a heatmap in order to investigate 
the distribution of hydrogen bonds across individual glycans, with a grid used to represent protomer divisions. Main 
upward-right diagonal shows intra-protomer interactions whereas the remaining blocks depict interprotomer interactions. 
Note: glycans 386 (Man9) and 462 (Complex) of Protomer 1, 185h (Complex) and 392 (Man9) of Protomer 2, and 363 
(Man9) of Protomer 3 were not added to this trimer (See Table 3), and thus are not shown on the heatmap. 
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Supplementary Table 1: Top 10 Ranked RMSF values used for delineating outliers 
RMSF values were ranked highest to lowest along with their sequence numbers. The sequence numbers which 
corresponded to the outliers caused by lack of positional restraints were excluded from the Mann-Whitney U test (italicised 
and highlighted in dark grey). The highest non-outlying value was 6.6927; thus 6.7 was set as the cutoff, and only RMSF 
values below this were used in statistical analysis.  
 
Man9-Trimer 
Sequence number 
RMSF 
Mixed-Trimer 
Sequence number 
RMSF 
1 750 13.53 1 750 9.26 
1 751 12.92 1 751 8.80 
1 752 11.70 1 752 8.30 
1 753 10.66 1 753 7.85 
1 754 9.35 1 754 6.64 
482 9.07 1 749 5.87 
483 8.28 372 5.72 
1 755 8.26 1 755 5.36 
484 6.94 373 5.35 
1 115 6.69 481 5.23 
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Supplementary Table 2: Ranking of glycan percentage contribution to hydrogen bonding  
 
Man9-Trimer Mixed-Trimer 
Glycan 
Number of 
hydrogen 
bonds 
% contribution 
to hydrogen 
bonding 
Glycan 
Number of 
hydrogen 
bonds 
% contribution 
to hydrogen 
bonding 
1_332_m9 85 525 4.01 1_137_c 91 363 3.43 
1_295_m9 79 020 3.70 2_462_c 79 922 3.00 
3_625_m9 66 264 3.10 3_295_m9 79 294 2.98 
3_88_m9 65 493 3.07 1_160_m9 77 144 2.89 
1_355_m9 62 174 2.91 1_133_m9 75 259 2.82 
2_185h_m9 61 914 2.90 3_160_m9 71 527 2.68 
2_625_m9 54 704 2.56 3_411_m9 69 310 2.60 
1_185h_m9 51 251 2.40 2_185e_c 68 089 2.56 
1_234_m9 48 675 2.28 1_185h_c 66 837 2.51 
3_406_m9 47 252 2.21 3_462_c 64 586 2.42 
2_88_m9 46 171 2.16 3_625_m9 64 266 2.41 
3_448_m9 44 781 2.10 3_156_m9 63 896 2.40 
3_295_m9 43 596 2.04 3_185h_c 62 637 2.35 
1_185e_m9 41 543 1.95 2_295_m9 61 025 2.29 
2_398_m9 40 942 1.92 1_262_m9 60 175 2.26 
2_406_m9 40 593 1.90 1_448_m9 58 078 2.18 
3_160_m9 39 596 1.86 2_234_m9 58 065 2.18 
1_156_m9 39 556 1.85 1_185e_c 56 791 2.13 
3_411_m9 37 640 1.76 3_332_m9 54 705 2.05 
2_156_m9 37 468 1.76 2_160_m9 54 419 2.04 
3_332_m9 37 375 1.75 2_332_m9 51 033 1.92 
2_137_m9 36 724 1.72 3_398_m9 44 718 1.68 
2_411_m9 33 948 1.59 2_137_c 42 163 1.58 
3_197_m9 33 922 1.59 2_301_m9 40 772 1.53 
2_462_m9 32 953 1.54 2_355_m5 40 246 1.51 
2_339_m9 31 983 1.50 1_332_m9 40 090 1.50 
3_301_m9 31 174 1.46 3_448_m9 40 010 1.50 
1_197_m9 30 539 1.43 3_137_c 38 235 1.43 
3_185e_m9 30 527 1.43 1_156_m9 37 231 1.40 
2_160_m9 30 343 1.42 3_234_m9 36 628 1.37 
1_398_m9 29 520 1.38 1_363_m9 35 904 1.35 
2_133_m9 29 513 1.38 3_637_m5 35 902 1.35 
1_160_m9 29 401 1.38 3_262_m9 35 494 1.33 
2_332_m9 28 292 1.33 2_156_m9 34 309 1.29 
2_637_m9 28 230 1.32 1_88_m9 33 690 1.26 
2_448_m9 27 239 1.28 3_301_m9 32 860 1.23 
1_386_m9 26 409 1.24 1_411_m9 32 279 1.21 
1_363_m9 25 482 1.19 2_411_m9 31 873 1.20 
3_392_m9 24 714 1.16 1_392_m9 28 124 1.06 
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3_386_m9 24 067 1.13 1_295_m9 27 449 1.03 
3_156_m9 23 782 1.11 3_618_c 27 048 1.02 
1_88_m9 23 750 1.11 1_625_m9 26 052 0.98 
3_339_m9 23 521 1.10 3_197_m5 25 183 0.95 
1_448_m9 21 601 1.01 3_88_m9 24 393 0.92 
2_386_m9 20 829 0.98 2_406_m9 23 387 0.88 
2_185e_m9 19 733 0.92 1_355_m5 22 879 0.86 
1_133_m9 18 464 0.87 1_398_m9 22 680 0.85 
1_137_m9 18 194 0.85 1_406_m9 22 515 0.84 
1_618_m9 17 587 0.82 1_618_c 22 495 0.84 
3_262_m9 17 553 0.82 3_386_m9 22 280 0.84 
3_133_m9 17 010 0.80 3_406_m9 22 120 0.83 
2_301_m9 16 139 0.76 1_234_m9 21 910 0.82 
1_637_m9 15 690 0.74 2_448_m9 19 072 0.72 
1_276_m9 15 485 0.73 2_262_m9 18 801 0.71 
1_611_m9 14 951 0.70 3_339_m9 18 677 0.70 
2_295_m9 14 815 0.69 3_185e_c 18 545 0.70 
2_276_m9 14 645 0.69 2_363_m9 17 615 0.66 
1_301_m9 14 619 0.68 1_339_m9 16 933 0.64 
1_411_m9 13 962 0.65 3_392_m9 16 549 0.62 
1_262_m9 13 533 0.63 2_618_c 13 682 0.51 
3_185h_m9 12 079 0.57 3_276_m5 13 043 0.49 
2_234_m9 11 618 0.54 3_355_m5 12 852 0.48 
2_262_m9 11 495 0.54 2_386_m9 12 520 0.47 
3_398_m9 11 367 0.53 2_276_m5 12 122 0.45 
1_462_m9 11 059 0.52 3_133_m9 11 763 0.44 
1_339_m9 10 778 0.50 2_339_m9 10 970 0.41 
3_462_m9 9 568 0.45 3_611_c 10 905 0.41 
3_234_m9 9 260 0.43 2_197_m5 10 113 0.38 
2_355_m9 8 889 0.42 1_197_m5 10 107 0.38 
3_355_m9 8 195 0.38 2_625_m9 8 304 0.31 
3_637_m9 7 916 0.37 2_133_m9 8 293 0.31 
1_625_m9 7 194 0.34 1_276_m5 7 955 0.30 
3_137_m9 6 632 0.31 2_398_m9 7 413 0.28 
3_276_m9 4 783 0.22 2_88_m9 6 817 0.26 
3_611_m9 3 661 0.17 2_611_c 6 338 0.24 
3_618_m9 2 662 0.12 1_637_m5 5 420 0.20 
2_197_m9 2 226 0.10 1_301_m9 5 234 0.20 
1_406_m9 1 789 0.08 2_637_m5 4 003 0.15 
2_618_m9 498 0.02 1_611_c 1 426 0.05 
2_611_m9 457 0.02       
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Supplementary Methods: Algorithms written for this project 
A. Core algorithm used for parsing the CPPTRAJ hydrogen bonding output 
Note to the reader: If you are not familiar with code, the lines beginning with # give a general 
description of the steps in the algorithm below.  
This code is related to Section 3.4.1. Quantifying the glycan interactions from simulations. 
 
 
def hbond_csv(hbonds, dct, rev): 
    ''' 
    INPUT: 
    - hbonds: converted csv output from the hbonds module in CPPTRAJ 
    - dct: glycan dictionary 
    - rev: & reverse dictionary mapping residues to glycans 
 
    OUPUT 
    - A csv file for every glycan, which contains a column for every interaction 
      that glycan has with another glycan 
        --> filename = glycan eg: N88 
        --> header names = glycan interactions for that glycan eg: N88-N133 
        --> each row a frame of summed hydrogen bonds in that glyc-glyc intxn 
    ''' 
    hbond_table = pd.read_csv(hbonds, header=0) 
    colheaders = list(hbond_table) 
    summed_dfs = {} 
    # {N88:{N88-N133:sdfs}, {N88-N37:sdfs}, N133 etc} 
 
    for glycan, res in dct.items(): 
        # eg dct: {'m1_88': ['482', '483', '484', ..., '491', '492'], ...} 
        #print(glycan) 
        summed_dfs[glycan] = {} 
        # creating a dictionary within a dictionary, populated by each pass of 
        # the for loop 
        interglyc = []  # header names of interglycan hydrogen bonding 
        # --> to use as a filter with the giant table 
        # eg: ["4YB_2607@O3-OMA_2799@O4-H4O", ...] 
        glyc_intxn_heads = []  # glycan names for the interglycan interactions 
        # --> to make human sense of each interaction and relate it back to the 
        # glycans we are dealing with 
        # eg: ["m1_133-m1_137", "m1_133-m2_88"] 
        for resid in res: 
            # print(resid) 
            for colname in colheaders: 
                # eg colname: 4YB_48@O3-4YB_26@N2-H2N 
                # eg extract_resids output: [48, 26] 
                print(resid, colname) 
                if resid in colname: 
                    print("resid {} in: {}".format(resid, colname)) 
                    res1, res2 = (extract_resids(colname))  # res1 & 2 are ints 
                    print("res1: ", res1) 
                    print("res2: ", res2) 
 
                    if resid != str(res1) and resid != str(res2): 
                        pass 
 
                    else: 
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                        if resid == str(res1): 
                            print("resid == res1") 
                            glycan_1 = glycan 
                            glycan_2 = rev[str(res2)] 
                            print(glycan_1, glycan_2) 
 
                        if resid == str(res2): 
                            print("resid == res2") 
                            glycan_1 = glycan 
                            glycan_2 = rev[str(res1)] 
                            print(glycan_1, glycan_2) 
 
                        if glycan_1 == glycan_2: # filter out m1_133 == m1_133 etc 
                            print("not including as intra-glycan interaction")  
                            # exclude column if glycans are the same through 
                            # if/else statement 
                        else: 
                            # we want to keep it 
                            if colname in interglyc:   
    # check if it's already there 
                                pass 
                            else:  
      # if not, add it to the interglyc list in form N88-N133 
                                interglyc.append(colname) 
                                    glyc_intxn_heads.append(str(glycan_1) + "-" + str(glycan_2)) 
 
                else: 
                    pass 
 
        if interglyc != []: 
 
            df_interglyc = hbond_table[interglyc] 
            # This is filtered down to just the interglycan hydrogen bonds 
            # So then need to see where the glycans are the same (eg: N88 & N133) 
            # and add these columns together 
 
            # Get the indices for every unique glycan interaction into a dictionary 
            intxn_indices = defaultdict(list) 
            for index, intxn in enumerate(glyc_intxn_heads): 
                intxn_indices[intxn].append(index) 
 
            # Use indices from above for each unique hbond to look up these columns 
            # and sum them (eg summing all N88-N133 interactions) 
            # --> summing by frame for each glyc-glyc interaction 
            for intxn in intxn_indices: 
                print("-->", intxn) 
                print(type(intxn)) 
                sum_df = df_interglyc.iloc[:, intxn_indices[intxn]].sum(axis=1) 
                summed_dfs[glycan][intxn] = sum_df 
                print(sum_df) 
            # Join the summed dfs into one df per glycan to show all its intxns 
            joined_dfs = pd.concat(summed_dfs[glycan], axis=1) 
 
            with open("{}.csv".format(glycan), 'w', newline='') as csvfile: 
                writer = csv.DictWriter(csvfile, fieldnames=False) 
                joined_dfs.to_csv(csvfile, index=False) 
 
    print("done :) \nCheck working directory for output csv files") 
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B. Core algorithms for calculating the hydrogen bonding by glycan 
This code is related to Section 3.4.1. Quantifying the glycan interactions from simulations. 
 
 
Step 1: Command Line 
 for file in *.csv; do python add.py -hb ${file} >> mixed_sums.txt; done #used on 
the .csv output by glycan from A 
 
Main contents of add.py: 
    hbond_table = pd.read_csv(sum_hbonds, header=0) 
    print(hbond_table.sum()) 
 
 grep -v dtype mixed_sums.csv > mix_clean.csv 
 
Step 2: Python 
man9_df = pd.read_csv('man9_clean.csv', header = None) 
mixed_df = pd.read_csv('mix_clean.csv', header = None) 
 
#making them sets in order to use operators on them for set theory  
man9_set = OrderedSet(man9_df[0])  
mixed_set = OrderedSet(mixed_df[0]) 
 
common_interactions = man9_set & mixed_set 
man9_only_interactions = man9_set - mixed_set 
mixed_only_interactions = mixed_set - man9_set 
 
man9_dict = dict(zip(list(man9_df[0]), list(man9_df[1]))) 
mixed_dict = dict(zip(list(mixed_df[0]), list(mixed_df[1]))) 
 
# Make a dictionary of the common interactions in the form:  
# {'m1_262-m1_295': [100, 7752], 'm1_625-m1_637': [672, 2401]  
# Then change to a dataframe for checking & collating 
commonintxns_dict = collections.defaultdict(list) 
for interaction in common_interactions: 
    commonintxns_dict[interaction].append(man9_dict[interaction]) 
    commonintxns_dict[interaction].append(mixed_dict[interaction]) 
commonintxns_df = pd.DataFrame.from_dict(commonintxns_dict, orient='index') 
 
# Make Man9 & mixed dictionaries of the form: 
# {'m1_262-m1_295': [100], ...} 
# Then change to a dataframes for checking & collating 
 
man9onlyintxns_dict = collections.defaultdict(list) 
for interaction in man9_only_interactions: 
    man9onlyintxns_dict[interaction].append(man9_dict[interaction]) 
m9onlydf = pd.DataFrame.from_dict(man9onlyintxns_dict, orient='index') 
 
mixedonlyintxns_dict = collections.defaultdict(list) 
for interaction in mixed_only_interactions: 
    mixedonlyintxns_dict[interaction].append(mixed_dict[interaction]) 
mixedonlydf = pd.DataFrame.from_dict(mixedonlyintxns_dict, orient='index') 
 
#Here: do check of glycan pairs and sums 
 
#First reindex dfs 
commonintxns_df_reindexed = commonintxns_df.reindex(reorder_intxn(commonintxns_df)) 
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m9onlydf_reindexed = m9onlydf.reindex(reorder_intxn(m9onlydf)) 
mixedonlydf_reindexed = mixedonlydf.reindex(reorder_intxn(mixedonlydf)) 
 
#Then reorder by reindex so that pairs end up next to each other 
paired_commonintxndf = commonintxns_df_reindexed.sort_index(axis=0) 
paired_m9intxndf = m9onlydf_reindexed.sort_index(axis=0) 
paired_mixintxndf = mixedonlydf_reindexed.sort_index(axis=0) 
 
#Check that each glycan interaction has a partner, and that the number of hbonds is the 
same 
if check_clause(paired_commonintxndf, 2) == True: 
    if check_clause(paired_m9intxndf, 1) == True: 
        if check_clause(paired_mixintxndf, 1) == True: 
             
            #remove zeros from 1 column dfs 
            paired_m9intxndf = zero_count(paired_m9intxndf, 0)[0] 
            paired_mixintxndf = zero_count(paired_mixintxndf, 0)[0] 
             
            # remove zeros in m9 column of common intxns 
            paired_commonintxndf, add_to_mixed = zero_count(paired_commonintxndf, 0)[:2] 
            # remove zeros in mixed column 
            paired_commonintxndf, add_to_m9 = zero_count(paired_commonintxndf, 1)[:2] 
                       
             
            #add in the values column to the relevant 1 column df, eg: 
#                         add_to_m9 [                   0  1 
#             m1_332-m1_448   1185  0 
#             m1_332-m1_448   1185  0 
#             m2_137-m2_185e   391  0 
#             m2_137-m2_185e   391  0 
#             m3_386-m3_462     18  0 
#             m3_386-m3_462     18  0] 
 
            add_to_m9_df = pd.Series.to_frame(add_to_m9[0][0]) 
            paired_m9intxndf = paired_m9intxndf.append(add_to_m9_df)             
            add_to_mixed[0][0] = add_to_mixed[0][1]   
     # Little bit roundabout, but needed to join  
            # to paired_mixintxndf on the same column index 
            add_to_mixed_df = pd.Series.to_frame(add_to_mixed[0][0]) 
            paired_mixintxndf = paired_mixintxndf.append(add_to_mixed_df) 
             
            # Take every second row of the dataset, so that you rule out duplicates  
      #(since paired) 
            clean_m9_df = paired_m9intxndf.iloc[::2] 
            clean_mixed_df = paired_mixintxndf.iloc[::2] 
            clean_common_df = paired_commonintxndf.iloc[::2] 
            #Check: 
            print("\ncommon sum \nm9: ", clean_common_df.sum()[0], "\nmixed: ", 
        clean_common_df.sum()[1]) 
            print("\nm9 only sum: ", clean_m9_df.sum()[0]) 
            print("mixed only sum: ", clean_mixed_df.sum()[0]) 
                         
            #Add up the number of hydrogen bonds for each glycan: 
            m9_hbond_by_glyc_df =(glycan_hbond_count(clean_m9_df, 0, 
M9_GLYCANS)).add(glycan_hbond_count(clean_common_df, 0, 
M9_GLYCANS)).transpose().sort_values(by=[0], ascending=False) 
            mix_hbond_by_glyc_df = glycan_hbond_count(clean_mixed_df, 0, 
   MIX_GLYCANS).add(glycan_hbond_count(clean_common_df, 1,  
MIX_GLYCANS)).transpose().sort_values(by=[0], ascending=False) 
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C. Core algorithm for sorting glycan hydrogen bonds by region 
This code is related to Section 3.4.2. Assessing how glycan-glycan hydrogen bonds cluster into the defined regions of HIV-
1 Env. 
 
 
#Regions dictionary (for glycans) 
regions_dict = {"C1": ["088"], "V1/V2": ["133", "137", "156", "160", "185e", "185h"], 
"C2": ["197", "234", "262", "276", "295"], "V3": ["301"], "C3": ["332", "339", "355", 
"363"], "V4": ["386", "392", "398", "406", "411"], "C4": ["448"], "V5": ["462"],  
"gp41": ["611", "618", "625", "637"]} 
res_regions_dict = reverso(regions_dict) 
 
hbond_table = pd.read_csv(hbonds_table, header = 0) 
hbond_regions = hbond_table 
 
reg1 = [] 
reg2 = [] 
 
for glycan in hbond_regions["Glycan1"]: 
    a = (glycan.split("_")[0].strip("m"), res_regions_dict[glycan.split("_")[1]]) 
    reg1.append("_".join(a)) 
 
for glycan in hbond_regions["Glycan2"]: 
    b = (glycan.split("_")[0].strip("m"), res_regions_dict[glycan.split("_")[1]]) 
    reg2.append("_".join(b)) 
 
hbond_regions["Glycan1"] = reg1 
hbond_regions["Glycan2"] = reg2 
 
 
D. Core algorithm for percentage hydrogen bond presence over the simulation  
This code is related to Section 3.4.4. Investigating hydrogen bond longevity versus strength of bonding. 
 
 
#Similar to B.1. this script is used with a batch script.  
# Used on the csv outputs from B.2. 
int_table = pd.read_csv(hbond_by_frame, header=0) 
    # print(int_table) 
    dict_hbond_counts = collections.defaultdict(list) 
 
    for header in int_table: 
        no_hbonds_for_intxn = 0 
        for x in int_table[header]: 
            if x >= 1: 
                no_hbonds_for_intxn +=1 
        dict_hbond_counts[header].append(no_hbonds_for_intxn/len(int_table)*100) 
 
    print(pd.DataFrame.from_dict(dict_hbond_counts, orient='index')) 
 
 
E. Core algorithms for percentage glycan involvement in hydrogen bonding over the simulation 
This code is related to Section 3.4.4. Investigating hydrogen bond longevity versus strength of bonding. 
 
 
 for file in *.csv; do sort -n $file | uniq -c >> frames_present.txt;done 
 grep -e m1 -e m2 -e m3 frames_present.txt | awk '{print $2}' > list_of_intxns 
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 grep -e m1 -e m2 -e m3 -B 1 frames_present.txt | awk '{print $1}' | grep -w -v 1 | 
grep -w -v '[^a-zA-Z0-9]' > frames_present_ordered_nos 
 awk -F- '{print $1}' list_of_intxns > glycs_ordered 
 paste -d, glycs_ordered frames_present_ordered_nos > no_frames_not_glyc.csv   
 #NB: Since this algorithm finds the frames where the glycan is not involved, a 
further step is then necessary 
 
 
F. Core algorithm for the glycan processing prediction analysis 
This code is related to Section 3.6. Investigating Enzyme and Solvent Accessible Surface Area as a Proxy for Glycan 
Processing 
 
m9_sasa_df = pd.read_csv("0MA_SASAs.csv", header=None) 
print(m9_sasa_df) 
m9_sasa_df = m9_sasa_df.T 
print(m9_sasa_df.iloc[0:3]) 
 
sasa_df = pd.DataFrame() 
 
acc_glyc = 0 
for x in m9_glycans: 
    print(x) 
    print(m9_sasa_df.loc[:, acc_glyc]) 
    glyc_frames = [m9_sasa_df.iloc[:, acc_glyc], m9_sasa_df.iloc[:, acc_glyc+1], 
m9_sasa_df.iloc[:, acc_glyc+2]] 
    glyc_values = pd.concat(glyc_frames) 
    print(glyc_values) 
    frames = [sasa_df, glyc_values] 
    sasa_df = pd.concat(frames, axis=1) 
    acc_glyc += 3 
 
m9_glycans = ['1_88_m9', '1_133_m9', '1_137_c', '1_156_m9', '1_160_m9', '1_185e_c', 
'1_185h_c', '1_197_m5', '1_234_m9', '1_262_m9', '1_276_m5', '1_295_m9', '1_301_m9', 
'1_332_m9', '1_339_m9', '1_355_m5', '1_363_m9', '1_386_m9', '1_398_m9', '1_406_m9', 
'1_411_m9', '1_448_m9', '1_462_c', '1_611_c', '1_618_c', '1_625_m9', '1_637_m5', 
'2_88_m9', '2_133_m9', '2_137_c', '2_156_m9', '2_160_m9', '2_185e_c', '2_185h_c', 
'2_197_m5', '2_234_m9', '2_262_m9', '2_276_m5', '2_295_m9', '2_301_m9', '2_332_m9', 
'2_339_m9', '2_355_m5', '2_386_m9', '2_398_m9', '2_406_m9', '2_411_m9', '2_448_m9', 
'2_462_c', '2_611_c', '2_618_c', '2_625_m9', '2_637_m5', '3_88_m9', '3_133_m9', 
'3_137_c', '3_156_m9', '3_160_m9', '3_185e_c', '3_185h_c', '3_197_m5', '3_234_m9', 
'3_262_m9', '3_276_m5', '3_295_m9', '3_301_m9', '3_332_m9', '3_339_m9', '3_355_m5', 
'3_386_m9', '3_392_m9', '3_398_m9', '3_406_m9', '3_411_m9', '3_448_m9', '3_462_c', 
'3_611_c', '3_618_c', '3_625_m9', '3_637_m5'] 
 
sasa_df.columns = m9_glycans 
 
C_frames = [] 
m5_frames = [] 
m9_frames = [] 
for col in sasa_df.columns: 
 
    if glycoform_dict[col.split("_")[1]] == "C": 
        C_frames.append(col) 
    if glycoform_dict[col.split("_")[1]] == "M5": 
        m5_frames.append(col) 
    if glycoform_dict[col.split("_")[1]] == "M9": 
        m9_frames.append(col)  
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